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INTRODUCTION 
 
 Dyspepsia  affects more than one-fourths of the general population in 
all industrialised countries and is a frequent reason for medical consultation. 
 Dysspepsia accounts for upto 7% of hospital visits and 40-70% of 
gastrointestinal complaints in general medical practice. Dyspepsia appears to 
have a significant impact upon quality of life. 
 The definition and management of dyspepsia have underwent a world 
of change with the advent of endoscopy.  
Endoscopy has opened new visitors, for treatment of upper 
gastrointestinal diseases, be it gastritis or malignancy. 
They have given as new options for conservative treatment where 
previously surgery or just re-assurance were the main stay. 
Notwithstanding just visualising the upper GI tract, biopsy and definitive 
approach for better goal oriented treatment, have become a possibility since 2 
decades thanks to upper Gastrointestinal endoscopy. 
Even in a terminally ill patients with a carcinoma esophagus an 
obstructive lesion, can be stented towards palliative means. 
But still inspite of the vast strides being made like the Endo USG, there 
are certain practical set backs in ground reality, which have to be assessed 
and addressed on a patient to patient basis. 
Endoscopy requires costly equipment, technical capability and a willing 
patient who can afford the procedure. 
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In the absence of one or any of these, a needy patient should not be 
denied a meaningful evaluation of his symptoms; Hence this effort was carried 
out to correlate symptoms and UGI findings on endoscopy. 
The present study was conducted to identify the UGI symptoms and 
determine its role in predicting endoscopic findings. 
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REVIEW OF LITERATURE 
MILESTONES IN ENDOSCOPY 
 
 
INTRODUCTION 
 *The earliest exploration of the interior of the human body was 
attempted in antiquity by Greek, Roman and Arab physicians peering into its 
orifices through specula, the dim illumination of candle or oil lamp being 
reflected internally with mirrors. 
* Rectoscopes were familiar to Hippocrates (460–377 BC). 
* Quite advanced three-and four-pronged dilatation specula were 
recovered from the ruins of Pompeii (AD 79). 
* Marasaumel in the Babylonian Talmud (AD 257) described vaginal 
specula 4. 
THE ERA OF ENDOSCOPY WITH RIGID INSTRUMENTS 
The earliest advances were made by urologists, perhaps because the 
female urethra is one of the shortest conduits into an interior viscus. On a 
tombstone in a Frankfurt cemetery an epitaph records: 
         . . . in memory of the devout deceased soul of Philipp Bozzini, 
medical doctor,German born. This urologist was the first who tried 
seriously to look into the hollow cavities of the human body by 
ingeniously conducted light . . . 
                    Philipp Bozzini was born in 1773, aged 35 years, published  his 
experience with the Lichtleiter (light conductor) which he designed to 
accommodate different sizes and shapes of specula for the various bodily 
orifices. The essential components of the instrument were a beeswax candle 
 4
as light source and a silver mirror to reflect the light through the speculum 
.This endeavour marks the beginning of the era of rigid endoscopes 4. 
In Paris in 1826 a speculum ‘urethro-cystique’ was demonstrated by 
Pierre Salomon Segalas to the members of the Academie des Sciences. 
This was modified from the Bozzini instrument and enabled Segalas to 
diagnose disorders of the urethra and bladder. It had a safety feature in a gum 
elastic catheter as introducer  4. 
           A year later, in the Boston Medical and Surgical Journal, an American, 
John Fisher, published an account of an instrument ‘involving the same 
principles as Segalas’ which he claimed to have devised while still a student 
in 1824. 
Fisher suggested Professor Patterson that galvanism might supply an 
answer to improved illumination of body cavities, a thought that preceded the 
actual introduction of electricity to endoscopy by some 50 years. 
A generation later, in 1853, another urologist in Paris, Antonin 
Desormeaux, rejecting the available electricity- storing batteries as too heavy 
to move around, introduced the use of a lamp burning a mixture of alcohol 
and turpentine. To this a series of endoscopic tubes, of various diameters to 
suit the different orifices, were fitted. His rectoscope, demonstrated to the 
Academie des Sciences, was 12 cm long and thereafter sigmoidoscopes of 
increasing length were manufactured. By around 1890 the length of the rigid 
steel tube stabilised at 30 cm. This remained standard for the sigmoid colon 
for 60 years until the advent of flexible fibreoptic models 4 . 
THE DEVELOPMENT OF ALIMENTARY ENDOSCOPY 
The shift of interest to the alimentary tract began in 1868 at a meeting 
of the Freiburg Society of Naturalists when Adolf Kussmaul – with the good 
sense to use a professional sword-swallower for the demonstration – passed 
down the oesophagus into his subject’s stomach a hollow, rigid metal tube – 
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the first gastroscope. Illumination was provided by a Desormeaux lamp 
attached proximally, but visibility was poor. 
In 1870 Joseph Leiter, a Viennese instrument maker worked on the 
development of cytoscopes with the urologist Maximillian Nitze. A number of 
others had been experimenting with loops of platinum wire as filaments for 
electric lamps, the current provided by galvanic batteries. Leiter and Nitze had 
some success when they devised a method of cooling the lamp and, in 1879, 
followed up a successful cytoscope with a crude gastroscope using the same 
technique. 
Leiter during his work with von Mikulicz, shifted the light to the distal 
end of the tube but retained Kussmaul’s technique for the introduction of his 
gastroscope . 
 The prototype oesophagoscopes and gastroscopes were moderately 
effective but general anaesthesia was required for most subjects.   
Fortuitously, in 1885, the International Exhibition of Electricity was held 
in Vienna. There Leiter saw Edison’s incandescent electric lamps and 
promptly adapted the endoscopes to incorporate them.  
At the end of the nineteenth century, Chevalier Jackson, a prominent 
American exponent of broncho-scopy, went on to develop, and successfully 
use, open- tube rigid oesophagoscopes and gastroscopes, under ether-
induced general anaesthesia.  
In 1896 Theodore Rosenheim, in Berlin, published his experience 
with a triple-tube gastroscope, the innermost tube bearing a row of short-focus 
lenses, the middle one a lighting system which had reverted to the use of a 
water-cooled platinum wire loop lamp and an outer tube with a scale of 
measurement. With existing instruments there remained the need to 
overcome the problem of the ‘blind’ areas of the stomach. 
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             George Kelling in Dresden, in 1898, devised a gastroscope with a 
flexible lower segment, the tip of which could be angulated with a rather 
clumsy system of wires controlled proximally; this instrument did not find wide 
favour. 
Elsner reintroduced, in 1911, the Rosenheim instrument modified with 
the safety device of a rubber tip for introduction. Despite the lens system 
being easily obscured by mucus and gastric contents, it was well taken-up 
and remained the standard gastroscope for the next 20 years. 
Meanwhile, in Munich, Michael Hoffman, an optical engineer, had 
shown that light, and an image, could be conducted around a bend with a 
flexible tube containing a row of prisms and lenses. This work may have 
facilitated the next important step in the evolution of gastroscopes 4 . 
THE ERA OF SEMI-RIGID ENDOSCOPES 
In 1920, in Munich, a charismatic physician, Rudolf Schindler 
improved old Elsner instrument  with a facility for insufflating air which largely 
overcame the problem of the lens smearing. It had the rubber tip mounted 
separately on an inner tube used on introduction and then withdrawn, and in 
its place a tube carrying the lens and light system was inserted. 
Schindler successfully used the modified Elsner gastroscope until 1932 
when he reported his experience with a semi-flexible successor in which the 
lower third was replaced by a flexible bronze spiral covered in rubber, 
resulting from a collaboration with the renowned Berlin instrument maker 
George Wolf (1873–1938). Together they devised an inner tube filled with 
short-focus lenses which could be bent in any direction to an angle of 34º 
without visual distortion. 
The use of this instrument in Rudolf Schindler’s uniquely capable 
hands spelled the end of the era of rigid endoscopy and the semi-flexible 
successor remained dominant until 1957.   His monographs on gastroscopy 
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and gastric mucosal pathology were groundbreaking and were read 
extensively in Europe and the US. Would-be endoscopists flocked to Munich 
for training. 
In the light of things to come, mention must be made of Heinrich 
Lamm, a medical student in Munich who, after hearing a lecture by Schindler 
in 1928, approached him and suggested that a bundle of glass rods might 
conduct light and images better than a system of lenses.   This was a clue 
relevant to endoscopy which was ignored by optical engineers, physicists and 
instrument makers for over a century. 
Later Schindler was given an appointment in Walter Palmer’s 
department in Chicago as a visiting professor and from this time, Chicago 
became the new Mecca of endoscopy and a by-product of Schindler’s 
immigration was the promotion in the US of serious interest in the 
manufacture of endoscopes. 
In 1941, the London surgeon Hermon Taylor had the Genito-Urinary 
Manufacturing Company devise a gastroscope with a flexible distal portion 
which, with proximal controls, greatly reduced the areas of the stomach that 
were difficult to visualise directly. This involved an increase in the diameter of 
the shaft and elongation of the rigid steel portion. Schindler and others in the 
US were critical of this endoscope 4. 
OESOPHAGOSCOPES: FURTHER MODIFICATIONS 
Until 1947, oesophagoscopes remained fundamentally unchanged 
from those used by von Mikulicz in the 1880s, except for the incorporation of 
an Edison lamp for illumination.  
Edwin Boros in the US, altered the Jackson instrument (to facilitate 
introduction) by having the most distal portion of the shaft rendered as a metal 
spiral coil, similar to that used in the Wolf–Schindler gastroscope; this section 
was then straightened out with a rod after full insertion. 
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This instrument was superseded in 1949 by the oesophagoscope 
manufactured by the Eder Instrument Company to the design of A Ray 
Hufford, especially when further improvement was made substituting a 
magnifying telescopic eyepiece for the previous lens-in-a-tube system. It 
became the standard instrument of the day. 
In London, meanwhile, as a few physicians in the UK began to 
undertake oesophagoscopy, Frances Avery Jones devised an easy-to-pass 
slim instrument.  
The Genito-Urinary Manufacturing Company made in 1956 a wide-
bore oesophagoscope with a distal flexible section and a proximal lighting 
system which overcame the disadvantages of the   By 1963, however, the 
principles of flexible fibreoptics were extended to oesophagoscopes and, in 
these, the excellent vision, the ease of biopsy and the later addition of a 
balloon dilatation facility eliminated the need for the traditional rigid 
instruments for almost all situations 4. 
THE THIRD ERA: THE APPLICATION OF FIBREOPTICS; 
FULLY FLEXIBLE ENDOSCOPES 
The birth of fibreoptic endoscopy in1954: 
Hopkins, Baird’s and Karl Storz were working independently over  
the idea of coupling the transmission of light using fibres, an extension in 
effect of the idea of Hoffmann in Munich referred to earlier. 
With his postgraduate fellow Kapany, Hopkins researched the optimum 
way to coat glass fibres of 0·0025-inch diameter and to arrange them in a 
bundle so that the spatial relationship of each fibre to its neighbour remained 
unchanged throughout the length of the bundle. Light and image could then 
be transmitted even if the bundle was bent through 360º. They suggested the 
principle could replace the lens in endoscopes. 
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By 1956, Curtiss and Hirschowitz had resolved the problem of 
eliminating leakage of light through the wall of individual fibres by coating 
them with a mixture of highly refractive glass core and low refractoriness, 
melted together. 
A year later they had an assembly of a working fibre bundle of 
adequate length, a light source intense enough for colour photography, a 
system for applying torque and a waterproof coating overall. Hirschowitz then 
passed this bundle on himself without medication or surface anaesthesia and, 
a week later, successfully on a patient Fibreoptic, fully flexible endoscopy was 
born. At a meeting in 1957 of the American Gastroscopy Society, Hirschowitz 
successfully demonstrated the prototype. 
Three years later, in 1960, ACMI Ltd produced the first commercial 
gastroscope, a side viewing instrument with a distal incandescent lamp.  
In 1962 Robert Kemp, a Liverpool gastroscopist, suggested the 
introduction of a controllable directional tip which, taken up by ACMI, greatly 
improved the capability of the gastroscope. 
The Olympus Company introduced a lens-based gastro-camera, the 
film capsule of which lay in the tip of the gastroscope, but it had limited appeal 
and was soon replaced by effective 35 mm cameras with synchronised 
flashes which were mounted on the eyepiece 4 . 
EXTENSION OF ENDOSCOPY TO THE PANCREAS AND BILIARY 
SYSTEMS 
In 1966 Willie Watson, a Glasgow gastroenterologist viewed the 
Papilla of Vater. Indeed, in 1965, two radiologists, Keith Rabinov and Morris 
Simon, had cannulated the pancreatic duct with a tube introduced through the 
mouth and fluoroscoped into position. In 1968, the ampulla was cannulated 
per endoscopy. 
 10
             By 1970, largely due to ideas from Itaru Oi and K Tagaki, Japanese 
endoscope manufacturers produced cannulae with four-way tip control which 
greatly widened the field of investigation. In 1974, Classen and Demling split 
the Papilla of Vater with a bowstring wire diathermy enabling the removal of a 
gallstone from the biliary tract. 
In Britain Peter Cotton, first at Middlesex Hospital and later at the 
Dukes and Carolina venues in the US, became the premier exponent, 
extending the procedures through from endoscopic sphincterotomy and 
removal of calculi to lithotripsy and the therapy of biliary and pancreatic 
Malignancy 4 . 
THE ERA OF ELECTRONIC DEPENDENT ENDOSCOPY AND THE 
FUTURE 
In 1983 the first endoscope without fibreoptic transmission of the image 
was produced by Welch Alleyn Inc. in New York. At the tip of the instrument 
was an electronic sensor consisting of a packed grid of photocell receptors 
which transmitted images electronically to a video processor and then to a 
television monitor. 
Improved versions became available from the Olympus Company and 
other Japanese manufacturers. Subsequently, linkage with a computer 
enabled automated acquisition of data.   
Major changes in practice included the extension of the diagnostic and 
therapeutic capabilities of endoscopists to the pancreatic and biliary systems 
and the use of per-ampullary probes, balloons, retrieval baskets for stones 
and stents for strictures and screening malignancy in situ. The need for intra-
abdominal surgery was further restricted.  
A major advance, is the incorporation of ultrasound technology. The 
use of ultrasonic pulses for measuring biological changes in tissues was 
promoted 50 years ago by JJ Wild.  
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A series of studies of ultrasonic probes attached to endoscopes, later 
with miniaturised probes passed through the endoscope channels, has 
imaged lesions in the pancreas, mediastinum and in the peri-gastric and peri-
oesophageal tissues, thus facilitating enormously the evaluation of suspect 
malignancies, operability and also the variceal effects of portal hypertension 4 .    
Applications in the use of gastrointestinal endoscopy have continued to 
expand. Indeed a recent survey sponsored by British Society of 
Gastroenterology suggested that in near future, as many as 1% of the 
population will undergo upper gastrointestinal endoscopy annually 6. 
INSTRUMENTATION  
Flexible endoscopic systems transmit light down the endoscope shaft, 
illuminating the surface to be examined.the image is reflected back and 
transmitted to the endoscopist either fiberoptically or electronically. In 
fiberoptic systems, a fixed lens at the end of the instrument shaft focuses the 
reflected image on an internal fiberoptic bundle. Fiberoptic bundles are 2 to 3 
mm wide and are composed of  20,000 to 40,000 individual glass fibers, each 
approximately 10µm in diameter. Each fiber is coated with a glass of low 
optical density, which prevents light from escaping. The scope head includes 
an eyepiece with an adjustable lens; dials which control lens tip deflection; 
buttons controlling air, water, and suction; and the therapeutic channel inlet 7. 
Most modern systems utilize electronic image transmission . These 
video endoscopes are very similar to the fiberoscopes, offering similar depth 
of focus, field of view, and tip deflection. The image is reflected on a charge-
coupled device ( CCD ) chip mounted on the shaft end. The chip’s image 
contains 30,000 to 150,000 pixels; resolution improves with increasing pixel 
numbers.The electronic image is transmitted through wires to a video 
processor in the instrument head 7. 
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There are two types of colour CCD chips. The earliest devices utilized 
a mosaic chip, which contains extra pixelsand allows primary-colour filters to 
be overlaid on the black and white image. These chips can be used with 
standard xenon light sources. Newer colour video endoscopes use sequential 
chips, in which all pixels are sequentially illuminated with the light of the three 
primary colours, alternating each colour 20 to 30 times per minute. Each 
coloured image is stored transiently in the image processor before being fed 
to the electron guns in the television monitor. Sequential chips are smaller 
and can easily mounted on smaller diameter endoscopes. Although they offer 
better resolution, sequential chips require larger, more expensive light source/ 
processor units 8. 
DEFINITION OF GASTROINTESTINAL (GI) ENDOSCOPIC 
PROCEDURES 
Esophagogastroduodenoscopy (EGD) affords an excellent view of 
mucosal surfaces of the esophagus, stomach, and proximal duodenum. 
Standard diagnostic functions include inspection, biopsy, photography and 
video recording. Diagnostic observations are made concerning focal benign or 
malignant lesions, diffuse mucosal changes, luminal obstruction, motility, and 
extrinsic compression by contiguous structures. The most common 
therapeutic endoscopic procedures include polypectomy, dilatation of 
strictures, removal of foreign bodies, gastrostomy, and treatment of 
gastrointestinal bleeding with injection, banding, coagulation or sclerotherapy.  
Endoscopic retrograde cholangiopancreatography (ERCP) employs 
endoscopy to identify the major and minor papillae. The biliary and pancreatic 
ductal systems are cannulated and opacified with contrast material to provide 
diagnostic information. Other diagnostic tools may be used in conjunction with 
ERCP including brush cytology, biopsy, and endoscopic ultrasound. 
Therapeutic maneuvers included with ERCP include endoscopic 
sphincterotomy with or without stent placement and with other ancillary 
techniques for the treatment of pancreatic and biliary duct disease 5. 
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GENERAL INDICATIONS 9 
These guidelines are based on a critical review of available information 
and broad clinical consensus, and are as specific and definitive as possible. 
Clinical considerations may occasionally justify a course of action at variance 
with these recommendations. 
GI ENDOSCOPY IS GENERALLY INDICATED: 
1.  If a change in management is probable based on results of endoscopy. 
2.  After an empiric trial of therapy for a suspected benign digestive 
disorder has been   unsuccessful. 
3.  As the initial method of evaluation as an alternative to radiographic 
studies. 
4.  When a primary therapeutic procedure is contemplated. 
GI ENDOSCOPY IS GENERALLY NOT INDICATED: 
1.  When the results will not contribute to a management choice. 
2.  For periodic follow-up of healed benign disease unless surveillance of 
a premalignant  condition is warranted. 
GI ENDOSCOPY IS GENERALLY CONTRAINDICATED : 
1.  When the risks to patient health or life are judged to outweigh the most 
favorable   benefits of the procedure. 
2.  When adequate patient cooperation or consent cannot be obtained. 
3.  When a perforated viscus is known or suspected. 
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SPECIFIC INDICATIONS STATEMENTS 9 
1. ESOPHAGOGASTRODUODENOSCOPY (EGD) IS GENERALLY 
INDICATED    FOR EVALUATING 
A.  Upper abdominal symptoms, which persist despite an appropriate trial 
of therapy. 
B.  Upper abdominal symptoms associated with other symptoms or signs 
suggesting serious disease (e.g., anorexia and weight loss) or in 
patients over 45 years of age. 
C.  Dysphagia or odynophagia. 
D.  Esophageal reflux symptoms, which are persistent or recurrent despite 
appropriate   therapy. 
E.  Persistent vomiting of unknown cause. 
F.  Other diseases in which the presence of upper GI pathology might 
modify other   planned management. Examples include, patients who 
have a history of ulcer or GI bleeding who are scheduled for organ 
transplantation, long-term anticoagulation or  chronic nonsteroidal anti-
inflammatory drug therapy for arthritis and those with cancer of the 
head and neck. 
G.  Familial adenomatous polyposis syndromes. 
H.  For confirmation and specific histologic diagnosis of radiologically 
demonstrated  lesions: 
1. Suspected neoplastic lesion. 
2. Gastric or esophageal ulcer. 
3. Upper tract stricture or obstruction. 
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I.  Gastrointestinal bleeding 
1.  In patients with active or recent bleeding. 
2.  For presumed chronic blood loss and for iron deficiency anemia 
when the clinical situation suggests an upper GI source or when 
colonoscopy is negative. 
J.   When sampling of tissue or fluid is indicated. 
K.   In patients with suspected portal hypertension to document or treat 
esophageal varices. 
L.   To assess acute injury after caustic ingestion. 
M.  Treatment of bleeding lesions such as ulcers, tumors, vascular 
abnormalities (e.g., electrocoagulation, heater probe, laser 
photocoagulation or injection therapy). 
N.   Banding or sclerotherapy of varices. 
O.   Removal of foreign bodies. 
P.    Removal of selected polypoid lesions. 
Q.   Placement of feeding or drainage tubes (peroral, percutaneous 
endoscopic  gastrostomy, percutaneous endoscopic jejunostomy). 
R.  Dilation of stenotic lesions (e.g., with transendoscopic balloon dilators 
or dilation systems employing guidewires). 
S.  Management of achalasia (e.g., botulinum toxin, balloon dilation). 
T.  Palliative treatment of stenosing neoplasms (e.g., laser, multipolar 
electrocoagulation, stent placement) are absent or respond adequately 
to ulcer therapy. 
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2.  EGD IS GENERALLY NOT INDICATED FOR EVALUATING: 
A.  Symptoms which are considered functional in origin (there are 
exceptions in which  an endoscopic examination may be done once to 
rule out organic disease, especially if symptoms are unresponsive to 
therapy). 
B.  Metastatic adenocarcinoma of unknown primary site when the results 
will not alter  management. 
C.  Radiographic findings of: 
          1.  Asymptomatic or uncomplicated sliding hiatal hernia. 
          2.  Uncomplicated duodenal ulcer which has responded to therapy. 
          3.  Deformed duodenal bulb when symptoms are absent or respond 
adequately to ulcer  therapy. 
3.  SEQUENTIAL OR PERIODIC EGD MAY BE INDICATED: 
Surveillance for malignancy in patients with premalignant conditions 
(i.e., Barrett’s  esophagus) 
4.  SEQUENTIAL OR PERIODIC EGD IS GENERALLY NOT INDICATED 
FOR: 
A.  Surveillance for malignancy in patients with gastric atrophy, pernicious 
anemia, or  prior gastric operations for benign disease. 
B.  Surveillance of healed benign disease such as esophagitis, gastric or 
duodenal ulcer. 
C.  Surveillance during repeated dilations of benign strictures unless there 
is a change in status 9 . 
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ANTIBIOTIC PROPHYLAXIS FOR GI ENDOSCOPY 
GI ENDOSCOPY AND THE RISK OF INFECTIOUS COMPLICATIONS 
The role of antibiotic prophylaxis is to reduce the possibility of a 
significant infectious complication. 
Despite the large number of endoscopic procedures performed 
annually, there are few case reports of bacterial endocarditis seen after the 
procedure. The reported cases of endocarditis were associated with 
procedures at high risk for bacteremia, such as esophageal dilation, 
esophageal sclerotherapy and    gastroscopy .Other rarely reported infectious 
complications associated with esophageal sclerotherapy and dilations have 
included bacterial peritonitis, central nervous system (CNS) infections, and a 
perinephric  abscess.  High-risk procedures are those procedures associated 
with a high incidence of bacteremia 10. 
The highest bacteremia rates have been seen in patients undergoing 
esophageal dilation of a stricture and in sclerotherapy of esophageal 
varices10. 
CONSENSUS STATEMENTS FOR ANTIBIOTIC PROPHYLAXIS DURING 
GI ENDOSCOPIC PROCEDURES: Recommendations. 
Prophylaxis against infective endocarditis : Regimens  
A.  Standard general prophylaxis:  
amoxicillin 2.0 g by mouth (adult) or 50 mg/kg by mouth (child), 1 hour 
before the procedure. Alternative for those unable to take by mouth is 
ampicillin 2.0 g IV/IM (adult) or 50 mg/kg IV/IM (child), within 30 minutes 
before procedure. 
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B.  Penicillin-allergic patients:  
           clindamycin 600 mg by mouth (adult) or 20 mg/kg by mouth (child),1 
hour before procedure. Alternatives: cephalexin or cefadroxil 2.0 g by mouth 
(adult) or 50 mg/kg by mouth (child), 1 hour before the procedure; 
azithromycin or clarithromycin 500 mg by mouth (adult) or 15 mg/kg by mouth 
(child), 1 hour before  the procedure. 
C.  Penicillin-allergic patients unable to take by mouth: 
clindamycin 600 mg IV (adult) or 20 mg/kg IV (child), within  30 minutes 
before the procedure. Alternative: cefazolin 1.0 g IV/IM (adult) or 25 mg/kg 
IV/IM (child) within 30 minutes before the procedure; vancomycin 1.0 g IV        
(adult) or 10-20 mg/kg (child) 10 . 
The patient with biliary obstruction, pancreatic pseudocyst, or 
pancreatic cystic lesion requiring FNA : Recommendation 
All patients undergoing ERCP for known or suspected biliary 
obstruction or known pancreatic pseudocyst should receive antibiotics along 
with adequate drainage of the biliary obstruction or cyst. Endoscopic 
transmural drainage of pancreatic pseudocysts, similarly,may result in the 
introduction of infection into the cystic cavity. In addition, the EUS-guided 
aspiration of pancreatic cystic lesions also may result in introduction of 
infection. 
Although not supported by randomized, controlled trials, the use of 
prophylactic antibiotics before attempted drainage of such pseudocysts and 
similar pancreatic lesions is recommended. Antibiotics that cover biliary flora 
such as enteric gram-negative organisms, enterococci, and possibly 
Pseudomonas sp. are recommended. Prophylactic antibiotics do not appear 
to be necessary before FNA of solid masses 10. 
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RECOMMENDATIONS 
•  Antibiotic prophylaxis against infective endocarditis is recommended 
when a high-risk patient is undergoing an endoscopic procedure 
associated with a high incidence for transient bacteremia.   
•  Patients undergoing high-risk endoscopic procedures who have a 
synthetic vascular graft less than 1 year old also should receive 
antibiotic prophylaxis. 
•  There is no clear benefit or consensus in the use of prophylactic 
antibiotics in patients with a prosthetic joint or an orthopedic prosthesis 
undergoing any endoscopic  procedure. 
•  All patients undergoing ERCP for known or suspected biliary 
obstruction or known pancreatic pseudocyst should receive antibiotics 
with adequate drainage of the biliary obstruction or cyst.  
•  Prophylactic antibiotics are recommended for EUS-guided aspiration of 
pancreatic cystic lesions but not before FNA of solid masses.   
•  All patients undergoing endoscopic placement of a percutaneous 
feeding tube should receive prophylactic antibiotics to limit the risk of 
soft-tissue infection.   
•  All patients with cirrhosis who present with GI bleeding should receive 
prophylactic antibiotics to decrease infectious complications and 
mortality 10. 
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PREPARATION OF PATIENTS FOR GI ENDOSCOPY 
INTERVENTIONS AND PRACTICES CONSIDERED 
General 
1. Perform preprocedure assessment of patient and review of medical 
records, including history of medical illnesses, medications, past 
surgery, previous endoscopies, and history of drug allergies or 
bleeding tendencies 
2. Obtain and record informed consent. 
3. Provide discussion of what will be done, expected discomfort, potential 
risks and benefits of the procedure including those of sedation, 
alternative methods of investigation or management. 
4. Provide instructions to restrict activities requiring alertness (e.g., 
driving, operating heavy or potentially harmful machinery, making 
legally binding decisions) until the effects of the medications are 
completely gone. 
5. Review instructions before procedure, and provide written instructions, 
including steps to follow in the event of a complication, upon 
discharge11.   
Upper Gastrointestinal (GI) Endoscopy 
1. Preprocedure fasting (no solids for 6 hours, no liquids for 4 hours 
before procedure) 
2. Topical pharyngeal anesthesia including 20% benzocaine spray 
3. Anticholinergic agents including atropine (not for routine use) 
4. Parenteral glucagons 11. 
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Endoscopic Ultrasound (EUS) 
1. Preparation as for upper GI endoscopy 
2. Sedatives 
3. Prophylactic antibiotics (for patients requiring fine needle aspiration 
[FNA] of cystic lesions) 11. 
Special Considerations 
1. Electronic monitoring of pulse, blood pressure, oxygen saturation, 
capnography and continuous electrocardiographic (ECG) rhythm 
2. Prophylactic antibiotics in patients undergoing certain procedures (e.g., 
esophageal dilation) in high-risk patients (e.g., prosthetic valve) 
3. Measurement of coagulation parameters and adjustments to 
anticoagulation therapy (e.g., aspirin or other nonsteroidal anti-
inflammatory drugs), if necessary 
4. Cardiac monitoring during use of electrosurgical equipment in patients 
with cardiodefibrillators 
5. Administration of insulin/hypoglycemic agents in diabetic patients 11 
CONSENT  FOR ENDOSCOPY  
To protect the patient's right of self-determination, informed consent 
should be obtained and documented before the patient is medicated. This 
must include a discussion of what will be done, expected discomfort, potential 
risks and benefits of the procedure including those of sedation, alternative 
methods of investigation or management, and the opportunity to ask 
questions12 -14. Appropriate efforts are needed to address specific 
circumstances resulting in any patient's inability to provide informed consent.  
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MEDICATION FOR ENDOSCOPY 
Medication before and during endoscopic procedures may be used to 
diminish GI secretions or motility, decrease the patient's anxiety or discomfort, 
and to provide amnesia 15. 
The guiding principle must be patient comfort and safety. General 
anesthesia or the presence of an anesthesiologist is indicated in special 
circumstances. The ASGE has recently published guidelines on the use of 
deep sedation and general anesthesia during endoscopic procedures 16.  
Anesthetic agents such as propofol and sedation adjuncts such as 
droperidol, promethazine, and diphenhydramine are useful in certain patients 
undergoing endoscopic procedures. While propofol provides faster onset and 
deeper sedation than standard benzodiazepines and narcotics, as well as 
faster recovery, clinically important benefits have not been consistently 
demonstrated in average-risk patients undergoing standard upper and lower 
endoscopy. The routine use of propofol in these patients cannot currently be 
endorsed. For prolonged therapeutic procedures, these agents have been 
demonstrated to be superior to standard benzodiazepine/ narcotic sedation 
and their use should be considered . Deep sedation requires more intensive 
monitoring by trained individuals. The assistance of anesthesiologists should 
be considered in patients undergoing prolonged therapeutic procedures 
requiring deep sedation, those with anticipated intolerance of standard 
sedatives, and those at increased risk for sedation-related complications, 
such as patients with severe comorbidities or with anatomic variants 
increasing the risk of airway obstruction. The use of agents to achieve 
sedation for endoscopy must conform to the individual institution's  
policies 17-19. 
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Appropriate Personnel and Equipment for Propofol Use in an 
Endoscopic Procedure  Room 
• At least one person who is qualified in both basic and advanced life 
support skills (i.e., tracheal intubation, defibrillation, use of resuscitation 
medications) 
• Physiologic monitoring should include pulse oximetry, 
electrocardiography, and automated blood pressure measurement. 
Monitoring oxygenation by pulse oximetry is not a substitute for 
monitoring ventilatory function. 
• Equipment for airway management and resuscitation 
• Trained personnel dedicated to the continuous and uninterrupted 
monitoring of the patient’s physiologic parameters and administration of 
propofol 
• Extended monitoring with capnography should be considered, as it 
may decrease the risks during deep sedation 17 -19 . 
Guideline for Anesthesiology Assistance during Gastrointestinal 
Endoscopy 
Anesthesiologist assistance may be considered in the following situations: 
• Prolonged or therapeutic endoscopic procedure requiring deep 
sedation 
• Anticipated intolerance to standard sedatives 
• Increased risk for complication due to severe comorbidity (American 
Society of Anesthesiologists [ASA] class III physical status 
classification or greater) 
• Increased risk for airway obstruction due to anatomic variant 
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There has been recent interest in the use of propofol, a rapidly acting 
anesthetic that provides excellent sedation and amnesia with a significantly 
shorter recovery time when compared with sedatives and/or analgesics  17 -19 .   
The choice of sedative is largely operator dependent, but generally 
consists of benzodiazepines used either alone or in combination with an 
opiate. The most commonly used benzodiazepines are midazolam and 
diazepam. The efficacy of sedation with these two benzodiazepines is 
comparable 20. However, most endoscopists favor midazolam for its fast onset 
of action, short duration of action, and high amnestic properties. 
PHARYNGEAL ANESTHESIA 
Pharyngeal anesthesia is often used to suppress the gag reflex during 
procedures involving the upper GI tract. Commonly used topical anesthetics 
include benzocaine, tetracaine, and lidocaine. They are administered by 
aerosol spray or gargling. The effects last for up to 1 hour. Despite their 
widespread use, there are conflicting data on their benefit. One study has 
suggested that topical anesthesia produced no additional benefit when used 
with intravenous conscious sedation21, 22. Another study suggested that the 
benefit might be greatest for patients who are less than 40 years old, those 
undergoing the procedure for the first time, or patients who are particularly 
anxious 23.There are numerous case reports on the occurrence of 
methemoglobinemia after administration of topical anesthetics. This should be 
suspected by the presence of clinical “cyanosis” in the face of a normal 
arterial PO2 24.   
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POSTPROCEDURE MONITORING 25 
 
After completion of endoscopic procedures, patients are to be 
observed for adverse effects from either instrumentation or sedation. The 
length of the follow-up observation is dependent on the perceived risk to the 
patient. Patients may be discharged from the endoscopy unit or 
postprocedure recovery area once vital signs are stable and the patient has 
reached an appropriate level of consciousness. Despite the appearance of 
appropriate recovery, it is well recognized that patients may have a prolonged 
period of amnesia and/or impairedjudgment and reflexes after intravenous 
medications administered to induce sedation. 
Patients should be advised before the administration of sedatives that 
a prolonged period of impaired cognition may occur. They should be 
instructed to make plans not to drive, operate heavy or potentially harmful 
machinery, or make legally binding decisions. When sedatives are 
administered, a competent companion for discharge must accompany 
patients from the recovery area. Written instructions upon discharge are 
necessary as the amnestic period following sedation is variable. 
Postprocedure instruction on the signs and symptom of potential 
adverse outcomes and complications is also advisable. Patients should be 
given written instructions on steps to follow in the event of a complication, 
including a phone number where 24-hour-a day coverage is available in the 
event of an emergency 25. 
SPECIAL CIRCUMSTANCES 
No sedation 
Selected patients may be able to undergo endoscopic procedures with 
no sedation. Ultrathin endoscopes with diameter from 5.3 to 6 mm can 
improve the tolerability of upper endoscopy and may be used without 
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sedation26-28. In general, topical anesthesia is used. There are several studies 
demonstrating successful colonoscopy in patients who receive no sedation or 
sedation only if needed 29-32. Older patients, men, patients who are not 
anxious, or patients without a history of abdominal pain may have better 
tolerance of upper endoscopy or colonoscopy with little or no sedation. For 
procedures performed without medications, it is still prudent to use varying 
levels of monitoring as the situation demands. 
ROLE OF EGD IN UGI – BLEED 
DEFINITION 
Upper-GI bleeding refers to GI blood loss whose origin is proximal to 
the ligament of Treitz.  Acute UGIB can manifest as hematemesis, ‘‘coffee 
ground’’ emesis, the return of red blood via nasogastric tube and/or melena 
with or without hemodynamic compromise. Hematochezia (bright red blood 
per rectum) may occur in patients with extremely brisk UGIB 33. 
Upper gastrointestinal (UGI) bleeding is a common medical 
presentation for patients seen by gastroenterologists and is associated with 
significant morbidity, mortality and the use of healthcare resources 34, 35.  
Endoscopy should be considered a primary and pivotal early 
intervention in establishing the source of bleeding. Early endoscopy allows 
clinicians an opportunity for therapeutic interventions and estimation of an 
individual’s risk for recurrent bleeding34, 35. 
TIMING OF ENDOSCOPY 
Endoscopy with the intention of therapeutic intervention(s) should be 
considered strongly as an early intervention to control bleeding and prevent 
rebleeding. Several issues regarding the exact timing of endoscopy and post 
endoscopy management are less clear 36. 
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The timing of endoscopy remains a significant controversy and few 
studies actually address this issue directly. While intuitively endoscopy with 
the intent of a therapeutic intervention is expected to improve short-term 
medical outcomes, the use of early endoscopy is difficult to define. In general, 
most studies evaluate the use of endoscopy within 24 hours of presentation. 
However, it remains unclear regarding the most optimal timing within the first 
24 hours 36. 
Emergent endoscopy is generally performed for patients who cannot 
be hemodynamically stabilized, those presenting with orthostasis, 
tachycardia, shock and/or signs of continued bleeding. The rationale is that 
hemostasis can be achieved with therapeutic endoscopic intervention and 
provide clinicians an opportunity to stabilize the patient hemodynamically 36. 
In contrast, endoscopy may be performed under more controlled 
conditions (but within 24 hours) and after more complete resuscitation in 
patients who do not have evidence of continued bleeding and who are 
medically stable. Multiple studies have demonstrated that therapeutic 
endoscopy using epinephrine injection, sclerosing agents, electrocautery, 
heater probes and other hemostatic interventions facilitate early control of 
bleeding reduce rebleeding rates and improve short-term morbidity and 
mortality 36. 
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 NON VARICEAL UGI BLEED 
ENDOSCOPIC TREATMENT MODALITIES FOR GI HEMORRHAGE 
Injection  Methods.  
*  The method of action of injection therapy is primary tamponade 
because of volume effect, with some agents having a secondary 
pharmacologic effect. Agents available for injection to produce 
tamponade include normal saline solution and epinephrine 
(adrenaline).  
* Sclerosants such as ethanol, ethanolamine, and polidocanol are not 
used to produce tamponade but instead cause direct tissue injury and 
thrombosis.  
*  Agents also can be used in combination (such as epinephrine followed 
by ethanolamine).Limited data suggest that higher volumes of 
epinephrine injected at endoscopy have a superior effect in achieving 
hemostasis 37. 
*  A separate class of injectable agents includes thrombin, fibrin, and 
cyanoacrylate glues, which are used to create a primary tissue seal at 
a bleeding site 38.  
*  Thrombin has been used in several studies in conjunction with heat 
probe therapy 38 and epinephrine injection 39, 40. 
Cautery 
*  Cautery devices include heat probes neodymium-yttrium aluminum 
garnet lasers, argon plasma coagulation (APC), and electrocautery 
probes. Laser therapy is not widely used in many centers because of 
cost, training, and support issues.  
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*  Electrocautery refers to the use of monopolar electrocauteryor bipolar 
(multipolar) electrocautery. 
*  Heat probes and electrocautery probes also use local tamponade 
(mechanical pressure of the probe tip at/ on the bleeding site) 
combined with heat /electrical current to coagulate (and thus close) the 
vessel in question, a process known as coaptation. 
*  Argon plasma coagulation uses a stream of ionized gas to conduct 
electricity resulting in coagulation of superficial tissues. Argon plasma 
coagulation is primarily used for the treatment of superficial lesions, 
such as vascular abnormalities, but may have a role in some patients 
with bleeding from other causes 41.  
Mechanical Therapy 
Mechanical therapy refers to the implantation of a device that causes 
physical tamponade of a bleeding site. Currently, the only mechanical 
therapies widely available are endoscopically placed clips and band ligation 
devices. 
Endoscopic clips usually are placed over a bleeding site (e.g., visible 
vessel) and left in place. Clips currently are available in two or three pronged 
configurations, can be affixed to bleeding sites, and typically slough off days 
to weeks after placement 42. 
BLEEDING GASTRIC OR DUODENAL ULCERS 
Gastric or duodenal ulcers (Figure 1, F) are the most common causes 
of UGI bleeding and there is a large volume of literature evaluating the 
prognosis associated with the endoscopic treatment of high risk ulcer lesions 
43. At the time of endoscopy and in the presence of gastric or duodenal ulcers, 
a test for Helicobacter pylori should be obtained. When positive, H.pylori 
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eradication has been shown to reduce the long-term (1 year) rate of 
rebleeding as compared to no treatment 44. 
ACTIVELY BLEEDING ULCERS AND ULCERS WITH NON-BLEEDING 
VISIBLE VESSELS 
Actively bleeding ulcers and ulcers with nonbleeding visible vessels are 
associated with the greatest risk of poor outcomes and / or re-bleeding  and  
are  seen collectively in up to 35% of patients with ulcers at the time of 
endoscopy 45. For this reason,  endoscopy  should  be  always  performed  
with  the  intention  for   therapeutic intervention.  Endoscopic therapies  may  
include  injection  of  epinephrine  and /  or sclerosants, electrocautery, heater 
probe or a combination of injection with subsequent thermal therapies. While 
the optimal choice of therapy is debated, studies repeatedly show that the use 
of these hemostatic therapies reduce the rate of re-bleeding as compared to 
no intervention. 
RECURRENT BLEEDING AFTER ENDOSCOPIC TREATMENT 
Despite adequate initial endoscopic therapy, recurrent bleeding in 
patients with UGIB can occur in up to 24% of high-risk patients, although 
more recent studies that emphasize the use of PPI therapy in addition to 
combination endoscopic therapy show recurrent bleeding rates of 
approximately 10% 46, 47. Studies suggest that if re-bleeding occurs, it will be 
within 48-72 hours 48 -50.  .Patients with recurrent bleeding respond favorably 
to repeat endoscopic therapy.  
Scheduled repeat endoscopy (e.g., at 24 hours) has been advocated 
for patients with high-risk stigmata that were treated at the time of the initial 
bleed 51. 
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PREDICTORS OF RE- BLEEDING 52 
1.  Older age 
2.  Shock/hemodynamic instability/orthostasis 
3.  Comorbid disease states (e.g., coronary artery disease, congestive 
heart  failure, renal and hepatic diseases, cancer) 
4.  Specific endoscopic diagnosis (e.g., GI malignancy) 
5.  Use of anticoagulants/coagulopathy 
6.  Presence of a high-risk lesion (e.g., arterial bleeding, nonbleeding, 
visible vessel and clot) 
Recent data has suggested that patients with overlying/ adherent clots 
may benefit from removal of the clot and therapeutic intervention based on the 
appearance of the ulcer base 53. A clot may be removed by simple irrigation to 
expose the underlying ulcer bases. If the clot dislodges, the ulcer base can be 
inspected for the presence of a visible vessel or acute bleeding; appropriate 
action can be taken. If the clot remains adherent, the endoscopist may opt for 
medical management. Alternatively, if the clot cannot be removed by simple 
irrigation, a preliminary study reports reduced rate of bleeding with 
epinephrine injection into the base of the base of the adherent clot, by clot 
removal and application of thermal contact therapy 54. 
ROLE OF EGD IN VASCULAR ABNORMALITIES 
Vascular malformations typically cause microscopic chronic blood loss 
and, occasionally, acute GI hemorrhage. These lesions can occur sporadically 
or in association with other disorders: cirrhosis, renal failure, radiation injury, 
various collagen vascular diseases, and hereditary hemorrhagic 
telangiectasia (Osler-Weber-Rendu disease). Endoscopic ligation 55, laser, 
APC, contact cautery, and sclerotherapy have been reported to be effective56. 
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There are no prospective trials comparing treatment methods for acute UGIB 
caused by vascular malformations.  
Dieulafoy’s lesion typically presents with intermittent, recurrent UGIB 57.  
Endoscopic methods to treat Dieulafoy’s lesion include banding, clipping, 
electrocautery, cyanoacrylate glue, sclerosant injection, epinephrine injection, 
heat probe, banding, and laser therapy. Large single-center experiences have 
not identified one modality as being superior to others, and no prospective 
randomized trials have been published 58 -60. 
ROLE OF EGD IN VARICEAL BLEED 
Variceal bleeding is a common and serious complication of portal 
hypertension. Mortality after the index hemorrhage in patients with cirrhosis 
has been reported to be as high as 50%, with a 30% mortality associated with 
subsequent bleeding episodes. 
SCREENING FOR ESOPHAGEAL VARICES 
Effective prophylactic treatments to prevent variceal bleeding exist for 
patients with esophageal varices. There no reliable methods of predicting 
which cirrhotic patients will have esophageal varices without endoscopy.  
An American Association for the Study of Liver Diseases guideline 
suggests that patients with Child’s stage A liver cirrhosis and signs of portal 
hypertension, specifically a platelet count of less than 140,000mm3 ,and / or 
enlarged portal vein diameter of greater that 13 mm or those classified as 
Child’s B or C at diagnosis should have screening endoscopy.  
Patients with cholestatic disease may have portal hypertension with 
relatively preserved liver function and platelet counts. A retrospective study of 
235 patients concluded that patients with either primary biliary cirrhosis or 
primary sclerosing cholangitis who have a count  <200/mm3 , an albumin level 
 33
<40 gm/L, and a bilirubin level >20 mmol/L should be screened for 
esophageal varices. 
Other groups recommend screening for all patients diagnosed with 
cirrhosis.  The optimal surveillance intervals for esophageal varices have not 
been determined. For patients found to have no varices on initial screening 
endoscopy, repeat endoscopy at 3-year intervals has been suggested, 
whereas patients with small varices should undergo endoscopy in 1 to 2 
years.     
Esophageal varices may grow faster in patients with cirrhosis 
secondary to alcohol abuse or severe liver impairment and in those with 
endoscopic stigmata of high risk (‘‘red wale markings’’); this subgroup of 
patients should undergo yearly upper endoscopy 61. 
PRIMARY PROPHYLAXIS 
Endoscopic sclerotherapy (EST) is not recommended for primary 
prophylaxis. While several studies have shown benefit, a well-done US study 
showed an increased mortality rate in the treated group. 
Endoscopic variceal ligation (EVL) eradicates esophageal varices with 
fewer complications than ESTand has been shown to be as effective as the 
use of beta-blockers 61. 
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ENDOSCOPIC TREATMENTS FOR VARICEAL  
HEMORRHAGE 
 
ENDOSCOPIC VARICEAL LIGATION 
EVL has become the treatment of choice both for controlling variceal 
hemorrhage and for variceal obliteration in secondary prophylaxis. 
A meta-analysis has confirmed the superiority of EVL over EST for all 
major outcomes (recurrent bleeding, local complications including ulceration 
and stricture formation, time to variceal obliteration, and survival). 
Recurrence of esophageal varices may develop more frequently in 
those treated with EVL, and regular endoscopic surveillance remains a critical 
aspect of management. 
The introduction of multiple-band firing devices has made EVL more 
widely acceptable and it is favored by many over EST for eradication of 
esophageal varices 61. 
ENDOSCOPIC SCLEROTHERAPY 
EST is successful in controlling active bleeding in over 90% of patients 
and can reduce the frequency and severity of recurrent variceal hemorrhage. 
Gastric varices in continuity with esophageal varices may be treated with EST 
below the  esophagogastric junction 61  . 
GASTRIC VARICES --- A SPECIAL MENTION 
Gastric varices are most commonly located in the cardia in continuity 
with esophageal varices. Isolated gastric varices are most commonly located 
in the fundus and can be seen in patients with cirrhosis and portal 
hypertension, as well as in patients with splenic vein thrombosis (e.g., from 
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pancreatic disease) or portal vein thrombosis. Bleeding from gastric varices is 
typically high volume in nature and can present with massive hematemesis. In 
general, endoscopic therapy for the treatment of bleeding gastric varices has 
been less successful than for esophageal varices. Treatment options that 
have been studied in prospective trials include injection of cyanoacrylate- 
based tissue adhesives, alcohol, sclerosants, and the use of band  
ligation 61. 
ROLE OF EGD IN OBSCURE GI BLEED (OGIB) 
Obscure GI bleeding (OGIB) has been defined as bleeding of unknown 
origin that persists or recurs after an initial negative endoscopic evaluation, 
including colonoscopy and/or upper endoscopy (EGD) 62. 
UPPER ENDOSCOPY 
EGD is indicated for the initial evaluation of a suspected upper GI 
source of bleeding. A repeat examination may yield a source even when the 
initial EGD was negative. One study suggested that up to 64% of lesions 
identified with a push enteroscope were within reach of a standard 
endoscope. The investigators suggested that repeat EGD should be 
considered before push enteroscopy (PE) for patients with OGIB. Conditions 
that might increase the yield of repeat EGD include large hiatal hernias and a 
history of NSAID use. If GI bleeding has not been documented clearly in the 
presence of iron deficiency anaemia (IDA), one must consider a small bowel 
biopsy to evaluate for celiac sprue at the time of EGD, although studies are 
mixed on the yield of small bowel biopsy in IDA 62. 
PUSH ENTEROSCOPY 
Push enteroscopy (PE), whereby a long endoscope is inserted into the 
jejunum through the mouth, is used to evaluate a larger segment of the small 
intestine, particularly in the setting of OGIB. The diagnostic yield is 
approximately 40% to 65% 62. 
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CAPSULE ENDOSCOPY 
Wireless video capsule endoscopy (CE) is a new technology that 
enables endoscopic evaluation of the small intestine. This new technology 
has the potential to identify a source of bleeding in patients with OGIB and/or 
IDA 62. 
SURGERY 
Intra-operative enteroscopy. Intra-operative enteroscopy (IOE) during 
laparotomy is typically used as a last resort in patients with OGIB requiring 
multiple transfusions and/or repeated hospitalizations 62.  
ROLE OF ENDOSCOPY IN THE SURVEILLANCE OF 
PREMALIGNANT CONDITIONS OF THE UPPER GI TRACT   63 
* Patients with chronic GERD at risk for Barrett’s esophagus should be 
considered for endoscopic screening . 
* In patients with Barrett’s esophagus without dysplasia, the cost 
effectiveness of surveillance endoscopy is controversial. If surveillance 
is performed, an interval of 3 years is acceptable . 
* Although an increased cancer risk has not been established in patients 
with Barrett’s esophagus and low grade dysplasia, endoscopy at 6 
months and yearly thereafter should be considered. 
*  Patients with Barrett’s esophagus with confirmed HGD should be 
considered for surgery or aggressive endoscopic therapy. Patients with 
HGD who elect endoscopic surveillance should be followed-up closely 
(ie, every 3 months) for at least 1 year. If no further HGD is confirmed, 
then the interval between follow-ups may be lengthened. 
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* There are insufficient data to recommend routine surveillance for 
patients with achalasia. 
* Patients with a severe caustic esophageal injury should undergo 
surveillance every 1 to 3 years beginning 15 to 20 years after the 
injury. 
* Patients with tylosis should undergo surveillance endoscopy every 1 to 
3 years beginning at age 30 years. 
* There are insufficient data to support routine endoscopic surveillance 
for patients with previous aerodigestive squamous cell cancer. 
* Adenomatous gastric polyps should be resected because of the risk for 
malignant transformation. Adenomatous polyps may recur in 
synchronous and metachronous sites, and surveillance endoscopies 
should be performed at 3- to 5-year intervals. 
*  Endoscopic surveillance for gastric intestinal metaplasia has not been 
extensively studied in the U.S. and therefore cannot be routinely 
recommended. However, there may be a subgroup of high-risk patients 
who will benefit from endoscopic surveillance . 
* Patients with confirmed gastric high-grade dysplasia should be 
considered for gastrectomy or local resection because of the high 
incidence of prevalent carcinoma.          
*  Patients with pernicious anemia may be considered for a single 
screening endoscopy, particularly if symptomatic, but there are 
insufficient data to recommend ongoing surveillance. 
* There are insufficient data to support routine endoscopic surveillance in 
patients with previous partial gastrectomy for peptic ulcer disease. 
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*  Patients with FAP should undergo regular surveillance endoscopy 
using both end-viewing and side-viewing endoscopes, starting around 
the time of colectomy or after the age of 30 years. 
* Patients with HNPCC have an increased risk of gastric and small-
bowel cancer. Surveillance should be strongly considered 63. 
COMPLICATIONS OF UPPER GI ENDOSCOPY 
Major complications related to diagnostic procedures can be broken 
down into cardiopulmonary complications, complications related to sedation, 
infectious complications, perforation, and bleeding. 
CARDIOPULMONARY COMPLICATIONS/ COMPLICATIONS RELATED 
TO SEDATION 
Cardiopulmonary complications related to sedation and analgesia are 
the most common type of complication seen with diagnostic endoscopy. 
These complications range from minor changes in vital signs to myocardial 
infarctions, respiratory depression, and shock / hypotension. 
It is estimated that oxygen desaturation may occur in up to 70% of 
patients undergoing various endoscopic examinations; more severe 
desaturation occurs less commonly. 
Sedation-related complications are generally identified during the 
procedure. Appropriate management includes “basic life support” if 
necessary. Proper management requires the presence of resuscitation 
medications, including reversal agents and equipment in all areas where 
endoscopy is performed 64. 
INFECTIOUS COMPLICATIONS 
Infectious complications related to diagnostic endoscopy result either 
from the procedure itself or from the use of contaminated equipment. 
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Transient bacteremia may occur during a diagnostic endoscopic 
procedureand is found more often for therapeutic procedures.Uncommon 
complications include retropharyngeal and retroesophageal abscesses in 
patients who have had difficult intubations. This may be related to 
retropharyngeal trauma and/or nonclinically apparent perforations should be 
considered 64. 
PERFORATION 
Perforation of the upper GI tract related to diagnostic endoscopy is 
relatively low.   Predisposing factors to perforations include the presence of 
anterior cervical osteophytes, Zenker’s diverticulum, esophageal strictures, 
and malignancies.  Although uncommon, perforations of the esophagus are 
associated with a relatively high mortality rate that approximates 25% 64. 
BLEEDING 
Significant bleeding is a rare complication of diagnostic upper 
endoscopy. Bleeding may be more likely in individuals with thrombocytopenia 
and/or coagulopathy. However, diagnostic upper endoscopy appears to be 
safe in patients with platelet counts as low as 20,000.1 Biopsies should be 
performed with caution below this level and platelet transfusions should be 
considered. Mallory-Weiss tears occur in <0.1% of diagnostic endoscopies 
and are usually not associated with significant bleeding 64. 
STRICTURE AND FISTULA  
These are known to occur following diagnostic and therapeutic 
modalities. Esophageal stricture formation can occur weeks to months after 
EVS sessions in 2% to 20% of patients. This can be diagnosed by upper 
gastrointestinal series and/or endoscopy 64. 
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ASPIRATION PNEUMONIA 
Up to 5% of patients may experience aspiration pneumonia after 
EVS64. 
Complications are known to occur in the following settings :  
a) Esophageal dilatation of  benign / malignant strctures and achalasia 
 
b) PEG  placement  
c) During endoscopic foreign body removal. 
d) During the treatment of esophageal malignancies by the mode of 
photodynamic therapy and also following endoprostheses placement 
(stent migration , hemorrhage and food impaction) 
e) During  endoscopic hemostatic procedures like endoscopic   variceal 
sclerotherapy  and endoscopic band ligation 64. 
ADVANCES IN ENDOSCOPY- ERCP 
INTRODUCTION 
ERCP was first reported in 1968 65 and was soon accepted as a safe, 
direct technique for evaluating biliary and pancreatic disease. With the 
introduction of endoscopic sphincterotomy in 1974 66, therapeutic 
pancreaticobiliary endoscopy subsequently was developed. ERCP is now 
widely available. 
ERCP IN BILIARY TRACT DISEASE 
ERCP is particularly useful in the management of the jaundiced patient 
with biliary obstruction because of choledocholithiasis and strictures. 
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Successful endoscopic cholangiography with relief of obstruction should be 
technically achievable in more than 90% of patients. Cholangioscopy at ERCP 
is used infrequently but may be helpful in the management of bile-duct stones 
and in assessing suspected malignancies 67. 
Choledocholithiasis  
The most common source of biliary obstruction is choledocholithiasis. 
Such patients may present with biliary colic, obstructive jaundice, cholangitis, 
or pancreatitis. The sensitivity and the specificity of ERCP for detecting 
common duct stones is over 95%;small stones occasionally are missed 68. 
Therapy for choledocholithiasis  
Endoscopic sphincterotomy and stone extraction is successful in more 
than 90% of cases, with an overall complication rate of approximately 5% and 
a mortality rate of less than 1% in expert hands 69. 
An alternative to biliary sphincterotomy is balloon dilation of the biliary 
sphincter (balloon sphincteroplasty). This may be an alternative to biliary 
sphincterotomy in selected patients with common bile duct stones, e.g., 
underlying coagulopathy, albeit with a higher risk of post-ERCP pancreatitis 
70, 71.    
ERCP IN MALIGNANT AND BENIGN BILIARY STRICTURES 
ERCP is useful in the assessment and the treatment of malignant 
biliary obstruction.Biopsies, brushings, and FNA may yield a definitive tissue 
diagnosis, but the combined sensitivity is no higher than 62% 72,73. 
ERCP is indicated for the evaluation and the treatment of benign bile-
duct strictures, congenital bile-duct abnormalities, and postoperative 
complications. This applies to patients with biliary obstruction after liver 
transplantation 74, 75. 
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Stricture dilation 
Benign biliary strictures may be dilated with hydrostatic balloons or a 
graduated catheter passed over a guidewire. 
Indications for endoscopic dilation of benign strictures include 
postoperative strictures, dominant strictures in sclerosing cholangitis, chronic 
pancreatitis, and stomal narrowing after choledochoenterostomy 76. 
           Stent placement may be used to maintain patency after initial dilation 
when using single or multiple endoscopic prostheses 77. 
Stents 
Endoscopically placed bile-duct stents have a role in the treatment of 
both malignant and benign biliary strictures, as well as in postoperative bile-
duct injuries or leaks 78. 
ROLE OF ERCP IN PANCREATIC DISEASE 79 
A. ERCP plays an important role in patients with recurrent acute 
pancreatitis and can identify and, in some cases, treat underlying 
causes.  
B.  ERCP is effective in treating symptomatic strictures in chronic 
pancreatitis. 
C.  ERCP is effective for the palliation of malignant biliary obstruction, for 
which self-expanding metallic stents have longer patency than plastic 
stents. 
D.  ERCP can be used to diagnose and to treat symptomatic pancreatic-
duct stones. 
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E.  Pancreatic-duct disruptions or leaks can be effectively treated via the 
placement of bridging or transpapillary pancreatic stents. 
F.  ERCP is a highly effective tool to drain symptomatic pancreatic 
pseudocysts and, in selected patients, more complicated benign 
pancreatic-fluid collections arising in patients with a history of 
pancreatitis. 
G.  Intraductal US and pancreatoscopy are useful adjunctive techniques 
for the diagnosis of pancreatic malignancies 79. 
ENDOSCOPIC ULTRASONOGRAPHY 
Advances in ultrasound technology led to transducer miniaturization, 
allowing for intra-coronary sonography in 1989 80. In the same year, initial 
experience with a mechanical linear ultrasound probe for evaluation of 
gastrointestinal use in the canine model was reported 81. High frequency 
ultrasound probe sonography (HFUPS) has aroused interest because it can 
be performed through the biopsy channel of an endoscope providing 
ultrasound imaging of visible lesions without the need for endoscope 
exchange. 
Technical Considerations 
Ultrasound probes for endoscopic use are available as 2, 2.4 and 2.6 
mm in with frequencies of 12, 15 and 20MHz and in lengths up to 220 cms. 
These high frequencies allow for detailed resolution of the gastrointestinal wall 
at the expense of depth of penetration. Reported mean imaging depths for the 
12 MHz and 20 MHz probes are 29 mm and 18 mm respectively 82, 83.  
           Probes consist of a mechanical rotating scanner with a protective 
cover, filled inside with oil that serves as an acoustica interface providing a 
360. radial image in a plane perpendicular to the probe axis. Mechanical linear 
images can also be obtained with one of the available systems. Scanning is 
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performed with the water immersion method or a balloon sheath placed over 
the probe.  
           In contrast to the five-layered gastrointestinal wall structure obtained 
with conventional EUS, HFUPS can delineate the 7 to 9 layered structure. 
The muscularis mucosae, not normally seen, is visualized as two layers in up 
to 70% of cases and the Muscularis propria as a three layered structure, 
circular layer, interface and longitudinal layer. This could have significant 
clinical relevance for endoscopic mucosal resections (EMR) or in the 
evaluation of motility disorders 84 - 87. 
Applications 
HFUPS has been used in the staging of esophageal, gastric, 
ampullary, pancreatobiliary, and colonic neoplasms. Reported accuracy in 
staging superficial esophageal carcinoma, early gastric cancer and flat 
colorectal tumors were 85%, 67 to 72.3% and 76 to 88% respectively. Local 
and peri-tumoral lymph nodes can be detected by HFUPS, but similar to 
conventional EUS cannot differentiate between benign of malignant nodes. 
Unlike conventional EUS, regional or deeper nodes cannot be visualized by 
HFUPS making it inadequate for TNM staging .Another application for HFUPS 
is in selecting the subgroup of patients with superficial neoplasms who are 
candidates for Endoscopic Mucosal Resection (EMR) 84-87. 
           Staging of ampullary and pancreaticobiliary malignancies has been 
reported by placing the ultrasound probes into the common bile duct and 
pancreatic ducts also referred as intraductal ultrasonography IDUS)  88, 89. 
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DYSPEPSIA 
DEFINITION  
“Dyspepsia is defined as a constellation of symptoms that include 
upper abdominal pain or discomfort, which is intermittent or constant and may 
be associated with additional symptoms of nausea and vomiting 90.”  
Although these symptoms may be associated with a wide range of 
specific clinical diagnoses (peptic ulcer disease [PUD], gastric cancer, and 
gastroesophageal reflux [GERD], among others), often no organic cause can 
be found (functional dyspepsia) 91. 
 Organic versus idiopathic dyspepsia. 
From an etiological viewpoint, patients with dyspeptic symptoms can 
be subdivided into 2 main categories 92: 
1.  Those with an identified organic or metabolic cause for the symptoms 
where, if the disease improves or is eliminated, symptoms also improve 
or resolve (eg, peptic ulcer disease, GERD with or without esophagitis, 
malignancy, pancreaticobiliary  disease, or medication use). 
2.  Those with no identifiable explanation for the symptoms. In some of 
these patients, an identifiable pathophysiological or microbiologic 
abnormality of uncertain clinical relevance   (eg, Helicobacter pylori 
gastritis) may be present, which is not thought to explain the 
symptoms.   Others have abnormal motor or sensory dysfunction (eg, 
altered gastric emptying, fundic dysaccommodation, or gastroduodenal 
hypersensitivity) of uncertain significance. This broad group of patients 
with idiopathic dyspepsia has   previously   been referred to as 
nonulcer dyspepsia, essential dyspepsia, idiopathic dyspepsia, or 
Functional Dyspepsia (FD). FD is currently the most recognized term in 
the literature. 
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DYSPEPTIC SYMPTOMS AND THEIR DEFINITIONS 92  
Epigastric pain 
Epigastric refers to the region between the umbilicus and lower                        
end of the sternum, and marked by the midclavicular lines. Pain                        
refers to a subjective, unpleasant sensation; some patients may                        
feel that tissue damage is occurring. Other symptoms may be                        
extremely bothersome without being interpreted by the patient                        
as pain. 
Epigastric burning  
Epigastric refers to the region between the umbilicus and lower                        
end of the sternum, and marked by the midclavicular lines.                        
Burning refers to an unpleasant subjective sensation of heat. 
Postprandial fullness 
An unpleasant sensation like the prolonged persistence of food                        
in the stomach 
Early satiation 
A feeling that the stomach is overfilled soon after starting to                        
eat, out of proportion to the size of the meal being eaten, so that                        
the meal cannot be finished. Previously, the term “early satiety”                       
was used, but satiation is the correct term for the disappearance                        
of the sensation of appetite during food ingestion 92. 
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CAUSES OF ORGANIC DYSPEPSIA 93 
 
A.  Luminal GI tract 
   a)   Food intolerance 
b)   Peptic ulcer disease 
c)  Gastroesophageal reflux 
d)  Gastric or esophageal neoplasms 
e)  Gastroparesis (diabetes, postvagotomy, scleroderma, chronic intestinal               
pseudo-obstruction) 
f)  In.ltrative gastric disorders (Menetrier’s syndrome, Crohn’s disease,             
eosinophilic gastroenteritis, sarcoidosis, amyloidosis) 
g)  Malabsorptive disorders (celiac sprue, lactose intolerance)  
h)  Gastric infections (CMV, fungal, TB, syphilis) 
i)  Parasites (Giardia lamblia, Strongyloides stercoralis) 
j)  Chronic gastric volvulus 
k)  Chronic intestinal ischemia 
l)  Irritable bowel syndrome  
B.  INTOLERANCE TO MEDICATIONS 93:           
o Ethanol, Aspirin/NSAIDs  
o Antibiotics (macrolides, sulfonamides, metronidazole) 
o Theophylline ,Digitalis, Glucocorticoid 
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o Iron, potassium chloride, Niacin, gemfibrozil 
o Narcotics, Colchicine, Quinidine 
o Estrogens, Levodopa 
o Nitrates, Loop diurectics, ACE inhibitors 
C.  PANCREATICOBILIARY DISORDERS 93:   
o Chronic pancreatitis 
o Pancreatic neoplasms 
o Biliary colic: cholelithiasis, choledocholithiasis, sphincter of Oddi 
dysfunction 
D.  SYSTEMIC DISORDERS 93:  
o Diabetes mellitus 
o Thyroid disease 
o Hyperparathyroidism 
o Adrenal insuf.ciency 
o Collagenvascular disorders 
o Renal insuf.ciency 
o Cardiac ischemia, congestive heart failure 
o Intra-abdominal malignancy 
o Pregnancy  
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FUNCTIONAL DYSPEPSIA 92 
A large group of patients with functional gastrointestinal disorders have 
chronic symptoms that can be attributed to the gastroduodenal region . Based 
on the consensus opinion of an international panel of clinical investigators 
who reviewed the available evidence, functional gastroduodenal disorders 
were classified as follows: 
CATEGORY B. FUNCTIONAL GASTRODUODENAL DISORDERS 
B1.  Functional dyspepsia 
        B1a.  Postprandial distress syndrome 
           B1b.  Epigastric pain syndrome 
B2.  Belching disorders 
B2a.  Aerophagia 
           B2b.  Unspecified excessive belching4 
B3.  Nausea and vomiting disorders 
B3a.  Chronic idiopathic nausea 
B3b.  Functional vomiting 
B3c.  Cyclic vomiting syndrome 
B4.  Rumination syndrome in adults 
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B1.  DIAGNOSTIC CRITERIA* FOR FUNCTIONAL DYSPEPSIA 92 
Must include: 
1.  One or more of: 
           a.  Bothersome postprandial fullness 
b.  Early satiation 
c.  Epigastric pain 
d.  Epigastric burning         
AND 
2.  No evidence of structural disease (including at upper endoscopy) that 
is likely to explain the symptoms. 
(*Criteria fulfilled for the last 3 months with symptom onset at least 6 
months before diagnosis) 
B1a. DIAGNOSTIC CRITERIA* FOR POSTPRANDIAL DISTRESS 
SYNDROME 92 
            Must include one or both of the following: 
1.  Bothersome postprandial fullness, occurring after ordinary sized                        
meals, at least several times per week. 
2.  Early satiation that prevents finishing a regular meal, at least several                        
times per week. 
(*Criteria fulfilled for the last 3 months with symptom onset at least 6 
months before diagnosis)               
Supportive criteria 
1.  Upper abdominal bloating or postprandial nausea or excessive                     
belching can be present. 
2.  EPS may coexist. 
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B1b.  DIAGNOSTIC CRITERIA* FOR EPIGASTRIC PAIN SYNDROME 92 
Must include all of the following: 
1.  Pain or burning localized to the epigastrium of at least moderate                        
severity at least once per week. 
2.  The pain is intermittent. 
3.  Not generalized or localized to other abdominal or chest regions. 
4.  Not relieved by defecation or passage of flatus. 
5.  Not fulfilling criteria for gallbladder and sphincter of Oddi disorders. 
(*Criteria fulfilled for the last 3 months with symptom onset at least 6 
months before diagnosis.) 
SUPPORTIVE CRITERIA: 
1.  The pain may be of a burning quality but without a retrosternal                        
component. 
2.  The pain is commonly induced or relieved by ingestion of a meal but                       
may occur  while fasting. 
3.  Postprandial distress syndrome may coexist. 
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PATHOPHYSIOLOGY 
The pathophysiologic characteristics of symptoms of functional 
dyspepsia are poorly understood. Dyspepsia is considered to be part of a 
continuum of functional GI disorders that involve the entire gut. 
A.   ABNORMALITIES IN GASTRODUODENAL MOTILITY   
1.  Delayed Gastric Emptying  
Delayed gastric emptying measures the integrated efficiency of     
gastric neuromuscular work in response to a meal 94. 
2.  Impaired Gastric Accommodation  
Ultrasonography, scintigraphy, and barostats have shown that in 
contrast to normal subjects, whose food is initially accommodated in the 
fundus and body with gradual redistribution to the antrum, over 40% of 
patients with functional dyspepsia have impaired accommodation of the 
proximal stomach, which may lead to early distribution of food to the distal 
stomach with dilatation of the antrum 95, 96.  
3.  Myoelectrical Abnormalities         
Noninvasive cutaneous electrogastrography (EGG) can measure 
fasting and postprandial gastric electrical activity. The basal electrical rhythm 
(BER) is generated by a pacemaker located in the proximal body and 
propagated longitudinally and circumferentially at a normal rate of 3 cycles per 
minute. Gastric dysrhythmias are identified by EGG in 40% of patients with 
functional dyspepsia but also in 20% of normal controls 97, 98. 
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B.  VISCERAL HYPERSENSITIVITY 
*  Afferent stimulation of gut mechanoreceptors reaches conscious 
perception through a three-neuron chain. 
*  Descending fibers from brainstem centers modulate the sensitivity of 
the dorsal horn neurons and control the perception of visceral 
sensation 99, 100. 
*  Most stimuli arising from the GI tract (accommodation, gastric 
emptying, distention, contractions) are not consciously perceived; 
however, a lowering of the perception threshold may occur in patients 
with functional dyspepsia, generating heightened sensitivity to normal 
physiologic events or minor noxious stimuli.61 Hypersensitivity to 
distention of the stomach can be demonstrated in more than 50% of 
patients with functional dyspepsia, both those who seek medical 
attention and non-consultors 101. 
C.  AUTONOMIC NEUROPATHY 
The vagus nerve regulates gastric accommodation and emptying and 
exerts a visceral antinocioceptive effect 101.     
           It is hypothesized that acute and chronic life stresses and 
psychological factors may lead to decreased vagal tone, which results in the 
pathophysiologic abnormalities that give rise to dyspeptic symptoms 102. 
D.  HELICOBACTER PYLORI  
           The prevalence of H. pylori infection in patients with  functional 
dyspepsia is similar to that in the general population. 
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           The strongest evidence against the role of H. pylori in functional 
dyspepsia is that controlled therapeutic trials of H.pylori eradication 
demonstrate no significant long-term improvement in symptoms 103. 
E.  PSYCHOSOCIAL FACTORS 
           The degree to which psychosocial factors are contributing and 
remediable should be assessed in every functional dyspepsia patient 104.  
           For many patients with functional dyspepsia, abdominal symptoms are 
part of a constellation of somatic and psychological complaints 105.  
ROLE OF H.PYLORI IN DYSPEPSIA 106 
Treatment of non-investigated dyspepsia may be different if the 
incidence of H. pylori is as low as occurs in developed countries. The 
increasing awareness of H. pylori as a pathogen in developing countries has 
stimulated interest in a test-and-treat approach in these areas. A test-and-
treat approach was recommended in adult patients below 45 years of age – 
the age cut-off may vary locally – presenting in primary care with persistent 
dyspepsia having excluded those with predominantly gastrooesophageal 
reflux disease (GORD), non-steroidal anti-inflammatory drugs (NSAIDs) 
consumption and those with alarm symptoms. This recommendation has been 
vindicated in more recent publications. The definition of low prevalence is a 
population with an infection rate of less than 20% 106. 
RECOMMENDATIONS 
•  H. pylori test and treat is an appropriate option for patients with non-
investigated dyspepsia. 
•  H. pylori eradication is an appropriate option for patients infected with 
H. pylori and investigated non-ulcer dyspepsia. 
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•  H. pylori test and treat is the strategy of choice in all (adult) patients 
with functional dyspepsia in high-prevalence populations. 
•  The effectiveness of H. pylori test and treat is low in populations with a 
low H. pylori prevalence. In this situation, the test-and-treat strategy or 
empirical acid suppression are appropriate options 106. 
TREATMENT 
TREATMENT OF FUNCTIONAL DYSPEPSIA: 93 
Most functional dyspepsia patients have intermittent, mild symptoms 
that respond to reassurance and life-style modifications. Refractory 
symptoms, however, may be difficult to manage. Lack of improvement may 
lead to concern that an organic cause has been overlooked and to repeated 
testing. 
Multicenter, Randomized Trials in Funcational Dyspepsia Comparing 
Resolution of Dyspepsia in Patients Treated with Proton Pump 
Inhibitors, Ranitidine, or Placebo. 
STUDY 
(REFERENCE) 
TREATMENT  
(DOSE) 
%TREATMENT
SUCCESS 
“Bond” Study Omeprazole (20 mg/day) 
Omeprazole (10 mg/day  
  Placebo 
43% 
43% 
26% 
“Opera” Study 
Omeprazole (20mg/day) 
Omeprazole (10 mg/day) 
Placebo 
34% 
30% 
31% 
 
Combined 
studies 
Omeprazole (20 mg/day)                          
Omeprazole (10 mg/day) 
Placebo 
38% 
36% 
28% 
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ANTISECRETORY AGENTS 
Antisecretory therapies —both H2-receptor antagonists and proton 
pump inhibitors—are useful in a subset of patients with functional dyspepsia, 
primarily those with heartburn or significant epigastric pain, and an empirical 
trial of such agents is reasonable. It is unlikely that they afford any significant 
benefit to patients with other dyspeptic symptoms. 
        In the subsets who benefit, it has not been established that proton 
pump inhibitors are superior to less expensive H2-receptor antagonists 93. 
PROMOTILITY AGENTS: 
Promotility agents decrease gastroesophageal reflux, improve gastric 
emptying, and facilitate accommodation and might thereby be predicted to 
benefit some patients with functional dyspepsia. 
A.  Domperidone, a peripherally acting dopaminergic antagonist does not 
cross theCNS blood-brain barrier, may be used, and it has shown 
considerable benefit. 
The high incidence of adverse CNS effects and extrapyramidal effects 
associated with metoclopramide makes it unsuitable for long-term use. 
Cisapride has been markedly restricted in its use by the United States 
Food and Drug Administration because of a low but significant risk of QT 
prolongation and cardiac tachyarrhythmias and should no longer be 
prescribed for functional dyspepsia 93. 
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TREATMENT OF H.PYLORI 
The European Consensus suggested that screening for H pylori 
followed by eradication therapy should be given to all dyspeptic patients 
younger than 45 years. 
BISMUTH-BASED TRIPLE THERAPY 
Bismuth compounds have been used for decades to treat dyspepsia 
and peptic ulceration—even before the anti–H pylori action of the compounds 
was known. The classic triple therapy of bismuth (colloidal bismuth subcitrate 
or bismuth subsalicylate), metronidazole, and either amoxycillin or tetracycline 
is the most common regimen. Tetracycline-containing triple therapy achieves 
a greater cure rate than the amoxicillin alternative. With a 1-week course of 
triple therapy, both duodenal and gastric ulcers heal—even without acid 
suppression by H2-receptor antagonists or proton pump inhibitors 107. 
DUAL THERAPY 
Dual therapy refers to the combination of PPIs or ranitidine bismuth 
citrate (RBC) and one antibiotic, usually amoxycillin or clarithromycin. 
Inhibition of acid secretion with a PPI or H2-receptor antagonist increases the 
intragastric acid level to pH5 or more and acts synergistically with amoxycillin 
and clarithromycin. 
These regimens are better tolerated and simpler to follow than 
bismuth-based triple therapy. The first dual therapy combining omeprazole 
with amoxycillin had unpredictable efficacy ranging from 20% to 90% and thus 
credibility with most gastroenterologists 107. 
TRIPLE THERAPY 
To date, the most popular treatment regimen for the cure of H pylori 
infection consists of an acid-suppressant (PPI or RBC) and two antimicrobial 
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agents PPI-triple therapy, no difference in the cure rate of H pylori infection 
and duodenal ulcer was found. One-week RBC-based triple therapy is now 
increasingly 107. 
The Metronidazole, Amoxycillin, Clarithromycin, Helicobacter (MACH)-
1 study tested omeprazole in combination with various antimicrobials 
(amoxycillin, tetracycline, and metronidazole) and confirmed the efficacy of 
this 1-week regimen. The best results were obtained from the therapies of 
omeprazole, clarithromycin, and amoxycillin or metronidazole. Their side 
effects are much milder than the original bismuth based triple therapy and 
patient compliance is expected to improve. The role of omeprazole in these 
non– bismuth-based triple therapies has been substantiated by the MACH-2 
study; the role appears to be a class effect of PPI.  
The choice of antibiotics decides the efficacy of PPI-based triple 
therapy 107.  
QUADRUPLE THERAPY 
Quadruple therapy combines an acid-suppressive drug, usually a PPI, 
with three antimicrobial agents. Typical quadruple therapy includes 
omeprazole, tetracycline, metronidazole, and a bismuth salt. Newer quadruple 
therapy may comprise another PPI, amoxycillin, clarithromycin, and 
metronidazole. Studies have been done to evaluate the possible role of 
quadruple therapy in shortening the duration of treatment or improving the 
efficacy of eradication 107.   
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AIM OF THE STUDY 
1. To evaluate patients with significant upper gastrointestinal symptoms 
by doing an UGI-Scopy  and analysis the various causes. 
2. To correlate symptoms with Endoscopic findings to determine the 
significance of a symptom as an indicator of diseasaes. 
3. To determine the importance of smoking, alcohol and NSAID's as 
etiological factors of upper GI disease as shown by UGI-scopy. 
 60
MATERIALS AND METHODOLOGY 
SELECTION CRITERIA OF SUBJECTS 
 Patients attending both medical / Medical gastroenterology OPD with 
UGI symptoms during the  period from Sep. 2004 to Sep. 2006 as a 
prospective study at Kilpauk Medical College and Hospital,Chennai. 
INCLUSION CRITERIA 
1. All patients presenting with UGI symptoms of pain abdomen 
(epigastric), heart burn, early satiety, bloating, vomiting, nausea, 
anorexia, loss of appetite, dysphagia and GI bleeding (for a period of 
more than 20 days). 
2. All patients of either sex above 15 years of age. 
3. Only those patients who consented for the procedure and underwent 
the same. 
EXCLUSION CRITERIA 
1. Age less than 15 years. 
2. Patients with cirrhosis, portal hypertension, corrosive poisoning or 
those undergoing renal transplant program, pre-surgical evaluation of 
umbilical hernia, gall stone disease or any other abdominal symptoms 
apart from UGI-symptoms. 
3. Patients undergoing follow up or a therapeutic endoscopy. 
METHODOLOGY 
• All patients were informed about the nature of the procedure and 
consent was obtained for the same. 
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• Patients who underwent UGI scopy on an elective list, were advised to 
come on an overnight fast or atleast a fast of 6-8 hrs minimum. The 
same will be applicable to inpatients also. 
• Dentures and spectacles were removed. 
• Patients were not sedated. 
• Cardiac assessment was obtained for patients where it was necessary. 
• Clinical monitoring of BP, Pulse, Respiratory rate, Oxygen Saturation 
during and after procedure in some cases as deemed necessary was 
done. 
• Pharyangeal anaesthetic solution was given for gargling just before the 
procedure. 
ENDOSCOPY 
U.G.I.Scopy was done  using a PENTAX for viewing fibre optic 
endoscopic. Only endoscopic findings were considered. Thus the diagnosis of 
oesophageal or gastric cancer was based on the presence of endoscopic 
features traditionally suggestive of malignancy. Oesophagitis was diagnosed 
according to criteria of Savary and Miller. In the absence of endoscopy 
stigmata of malignancy, gastric ulcer was considered as benign. 
The upper GI-symptoms with which the patients presented including  
upper abdominal pain, nausea, vomiting, heart burn, early satiety, bloating, 
dysphagia, weight loss, GI-bleed and anorexia were recorded.   
Details of tobacco use (smoking) alcohol, NSAIDS usage were 
recorded (including duration and frequency). 
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UGI endoscopy was performed and findings were recorded as follows: 
1. Normal study 
2. Oesophagitis/Oesophageal ulcer 
3. Carcinoma Oesophagus. 
4. Gastritis 
5. Gastric Ulcer 
6. Carcinoma Stomach 
7. Duodenal ulcer / Duodenitis 
8. Duodenal Stricture / GOO 
STATISTICAL ANALYSIS 
 Univariate analysis of each of the symptoms was correlated with the 
endoscopy outcome.  Statistical analysis was done using SPSS, Software and 
findings confirmed with the help of statistician. 
 63
OBSERVATIONS 
Data collected from 281 patients selected for study based on the 
inclusion criteria were analysed . Using the proforma the patients age, sex 
and personal habits were documented . All the presenting complaints of the 
patients, pertaining to the upper gastrointestinal system and their duration 
were also noted down. 
Patients selected for endoscopy were those with symptoms for atleast 
20 days, irrespective of previous history of treatment for these symptoms 
(except in the case of  malena / haemetemisis where  patient under went  
UGI-endoscopy at the earliest. 
PATIENT DEMOGRAPHY  
The study population consisted of 281 patients with a mean age of  44 
years . The youngest patient was 15 years old and the oldest 85 years . There  
were 76 females and 87 males below the age of 45 years  who under went 
UGI scopy. But on the whole out of 281 patients, 49.8% were males and 
50.2% were females. 
AGE DISTRIBUTION OF PATIENTS 
AGE IN YEARS MALE FEMALE TOTAL % 
15 to 30 41 32 73 25.97 
30 to 45 46 44 90 32 
45 to 60 25 39 64 22.8 
>60 28 26 54 19.21 
 140 141 281  
   
TABLE - 1 
             Among the 281 patients 33.8% were smokers and 14.6% were 
alcoholics,whereas 13.52% consumed both. Approximately 28% were 
consuming  NSAID,s regularly. 
 64
SYMPTOMS  VS DISEASE DISTRIBUTION 
S. 
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1 UPPER ABDOMEN PAIN 70.5 198 58 60 N 63 5 1 18 30 6 
2 HEART BURN 51.6 145 42 48 N 51 6 N 8 21 2 
3 NAUSEA 43.4 122 36 35 N 42 4 2 8 16 5 
4 VOMITING 34.5 97 24 31 1 32 1 2 7 14 5 
5 LOSS OF APPETITE 32.4 91 26 30 3 26 1 3 8 10 4 
6 BLOATING 18.9 53 20 13 N 14 2 2 4 8 4 
7 BELCHING 16.4 46 14 15 N 15 2 N 4 7 3 
8 EARLY SATIETY 14.9 42 16 10 N 12 1 3 3 4 3 
9 DYSPHAGIA 7.8 22 9 6 3 4 N 1 1 N N 
10 ANAEMIA 7.5 21 4 4 1 7 1 1 5 3 1 
11 UGI – BLEED 6 17 2 1 N 7 2 N 7 4 N 
12 LOSS 0F WEIGHT 5 14 3 N 3 2 N 3 2 N 2 
 
TABLE - 2
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ANALYSIS OF ENDOSCOPIC FINDINGS 
 
• Out of the 281 patients who presented with atleast one of the UGI 
symptoms 33.8% did not have any upper GI disease on endoscopy. 
• The most common finding on UGI scopy was gastritis ,30%, followed 
by reflux esophagitis at 26%. 
• Duodenal ulcer was 4 times more than gastric ulcer (25 vs 6 ). 
Approximately  12% also had duodenitis. 
• Out of the 84 patients who had gastritis, 75% presented with abdomen 
pain, 61% had heart burn and 50% of them had nausea. 
• Abdomen pain, heart burn, nausea and vomiting were the most 
common presentations in that order in patients diagnosed with 
esophagitis. 
• Among the 31 patients who had peptic ulcer disease (25-duodenal 
ulcer, 6- gastric ulcer), apart from abdomen pain and heart burn being 
the most common presentations, one third had lossof appetite,another 
one third presented with UGI bleed(malena / haematemesis ), and one 
fourth of them presented with anaemia. 
• Patients who had duodenal disease most commonly presented with 
upper abdomen pain. 
• Out of the six patients diagnosed with malignancy,3 had carcinoma 
esophagus and 3 carcinoma stomach. 
• Seven patients were diagnosed to have duodenal stricture , among 
which 4 patients developed gastric outlet obstruction, all of them males, 
who were regular smokers. 
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ANALYSIS OF  UGI SYMPTOMS AT  PRESENTATION  
• Upper abdomen pain was the most common complaint at presentation 
at 70%. 
• The next common presentation was heart burn (51.6%). 
• Nausea and vomiting were observed at 43.4% and 34.5% respectively. 
• Approximately 32% of the patients presented with loss of appetite. 
• One out of every five patients presented with bloating, belching, and or 
early satiety. 
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PREDICTORS OF ENDOSCOPIC FINDINGS WITH  RESPECT TO  DYSPEPTIC SYMPTOMS 
TABLE - 3 
UGI FINDINGS PRESENT 
S.No SYMPTOMS Symptom 
Present (%) 
Symptom 
Absent (%) 
Odds Ratio 95% CI 
p value 
(Pearson 
Chi-square) 
1 Upper abdomen pain 70.7 55.4 1.94 1.14 - 3.29 0.013(Sig) 
2 Heart burn 71 61 1.56 0.95 - 2.57 0.076(ns) 
3 Nausea 70.5 62.9 1.41 0.85 - 2.33 0.182(ns) 
4 Vomiting 75.3 61.4 1.91 1.10 - 3.29 0.020(Sig) 
5 Loss of appetite 71.4 63.7 1.42 0.83 - 2.44 0.199(ns) 
6 Bloating 62.3 67.1 0.80 o.44 - 1.49 0.502(ns) 
7 Belching 69.6 65.5 1.20 0.61 - 2.36 0.597(ns) 
8 Early satiety 61.9 66.9 0.80 0.41 - 1.57 0.524(ns) 
9 Dysphagia 59.1 66.8 0.718 0.30 - 1.70 0.463(ns) 
10 Anaemia 81 65 2.28 0.78 - 6.67 0.137(ns) 
11 UGI bleed 88.2 64.8 4.079 1.01 – 16.3 0.047(Sig) 
12 Loss of weight 78.6 65.5 1.93 0.562 – 6.56 0.315(ns) 
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Among 198 patients who presented with upper abdomen pain 71% 
had UGI disease and of those without abdomen pain 55.4% had positive UGI 
findings.  This difference  was statistically significant (p value of 0.013 ). 
TABLE  - 4 
UPPER ABDOMEN 
PAIN 
UGI 
DISEASE 
PRESENT 
UGI 
DISEASE 
ABSENT 
TOTAL % 
Present 140 58 198 70.7 
Absent 46 37 83 55.4 
 186 95 281  
 
                                           p value = 0.013 
 
Vomiting was found to be a statistically significant predictor of upper 
GI disease (p value of 0.020). Out of the 97 patients who presented with 
vomiting, one-third had esophagitis and one-third had gastritis, whereas 25% 
were not found to have any UGI disease on endoscopy. 
                                                 TABLE - 5 
VOMITING UGI DISEASE PRESENT 
UGI 
DISEASE 
ABSENT 
TOTAL 
% 
 
Present 73 24 97 75.3 
Absent 113 71 184 61.4 
 186 95 281  
    
                                                p value= 0.020                           
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¾ Among 74 patients with esophagitis, 57% presented with heart burn. 
¾ Seventeen patients presented with UGI bleed in the form of either 
malena or haematemesis or both, out of which 7 had doudenal ulcer, 2 
patients had gastric ulcer  and another seven patients had gastritis. 
Upper GI bleed was found to be a significant predictor of disease on 
endoscopy. 
¾ Upper GI endoscopy was indicated and done in 21 patients with 
anaemia, among whom 16 had UGI disease. For 9 of them the cause 
was in the stomach  (7-gastritis,1-gastric ulcer, 1-carcinoma stomach ), 
and the rest of them had duodenal disease (7-duodenal ulcer, 4-
duodenitis ). 
¾ Both loss of weight and loss of appetite were significant symptoms for 
predicting upper GI malignancy (Ca.stomach / Ca. esophagus ). 
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ANALYSIS OF THE INFLUENCE OF SMOKING ALCOHOL AND NSAID’S ON UPPER GI DISEASE 
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TABLE -6 
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PREDICTORS OF ENDOSCOPIC FINDINGS WITH RESPECT TO HABITS 
UGI Findings 
Present 
S.No HABITS Habits 
Present 
(%) 
Habits 
Absent 
(%) 
Odds 
Ratio 95% CI 
p value 
(Pearson 
Chi-square) 
1 SMOKING 82.1 58.1 3.31 1.82–6.00 <0.00003 (Sig) 
2 ALCOHOL 78 64.2 1.98 0.91–4.28 0.082(ns) 
3 NSAID’S 78.5 62.5 2.18 1.14–4.16 0.017(Sig) 
                                                                
TABLE –7 
 
33.8% of patients were smokers . 82% of smokers had disease, whereas 
only 58% of non-smokers, had UGI disease. The difference was statistically 
significant with a p value of < 0.0001. 
TABLE - 8 
            
SMOKING 
UGI DISEASE 
PRESENT 
UGI DISEASE 
ABSENT TOTAL 
% 
 
Present 78 17 95 82.1 
Absent 108 78 186 58.1 
 186 95 281  
                                    
p value <0.0001 
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NSAID’s usage was a significant factor in the causation of upper GI 
disease, with disease rates of 78.5% among those who regularly used them 
and the p value being statistically significant at 0.017. 
TABLE -9 
NSAID’s 
USAGE 
UGI 
DISEASE 
PRESENT 
UGI 
DISEASE 
ABSENT 
TOTAL 
% 
 
Present 51 14 65 78.5 
Absent 135 81 216 62.5 
 186 95 281  
 
p value = 0.017 
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DISCUSSION 
The term dyspepsia is used variably by health professionals to refer to 
a heterogeneous group of upper abdominal symptoms that may arise from 
numerous causes 108    . 
Regardless of numerous studies and trials dyspepsia still remains a 
controversial issue. 
In recent studies, the focus has been placed on the predominant 
symptom as a possible indicant of the underlying disorder, instead of 
classifying into symptom complexes and unspecified sub groups 109, 110. 
The advent of endoscopy has caused a sea of change in the definitions 
and management of dyspepsia , following which a new entity called functional 
dyspepsia has been defined, thanks to endoscopy. 
This study included 281 patients with a mean age 44 years, 58% were 
below the age of 45 years and 42% above 45 years . 
Abdomen pain  was the most common presenting symptom seen  in 
198 patients constituting  around 70.5% , and it turned out to be a significant 
predictor of upper gastrointestinal disease. This is comparable to a study by 
Kolk H where 73% of the patients had upper abdominal pain as the most 
common presenting symptom 111. 
Globally the prevalance of functional dyspepsia has been noted to vary 
between 11% to 29.2%. In this study around 33% of patients referred for 
endoscopy did not have detectable upper GI disease being at par 112. 
33.8% of the patients were smokers in this study and it was found that 
it was positively associated with with upper GI disease. A study by 
Moshkowitz M  et al, has similarly comparable findings and concludes that the 
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incidence of   significant upper GI disease is more prevalant in smokers with a 
p value of less than 0.05 113. 
There were 23.1% of patients in this study who had a history of regular 
NSAID’s usage and this was significantly attributable with upper GI disease. 
There were many studies confirming the same world over in different 
measures one among them was a study conducted by Devi DP et al in a 
south Indian hospital which implicates the NSAID’s to the same measure (p 
value <.005) 114. 
Out of 97 patients who presented with vomiting 75% had positive 
endoscopic findings one third of whom had reflux esophagitis. 
Also out of the 145 patients who had presented with heart burns one 
third had reflux esophagitis and another one third had gastritis. 
UGI bleeding is the only alarm symptom that definitely had  positive 
disease on endoscopy. 
Loss of weight and loss of appetite were significant predictors  of  
malignancy alone, as conformed by Adang et al 115. 
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SUMMARY 
 
¾ 281 patients presented with dyspeptic symptoms. 
¾ Age of the patients varied from 15 to 85 with a mean age of 44. 
¾ 163 patients (58%)were below the age of 45 years and 118 patients 
(42%) were above the age of 45 years. 
¾ Among the dyspeptic symptoms upper abdomen pain, vomiting and 
UGI-bleed(malena/ haemetemesis)were significant predictors of upper 
GI disease. 
¾  One third of patients with heart burns had relux esophagitis. 
¾ Roughly one third of the patients who presented with dyspeptic 
symptoms did not have any detectable ugi disease  on endoscopy. 
¾ Loss of weight and loss of appetite were significantly associated with 
upper GI malignancy. 
¾ Smoking habits and NSAID’s usage were definitely found to be 
causative factors of upper GI disease.  
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CONCLUSION 
  
Acid peptic disease still remains a common condition in the southern 
part of the country. The most common presenting symptoms are upper 
abdomen pain, heart burn, nausea and vomitting. Gastrititis, Reflux disease, 
duodenitis and peptic ulcer are the most common conditions we see. 
Although malignancy is one of the possibilities  it remains to have a low 
incidence compared to ulcer disease. 
The evaluation of symptoms to the pathology in the upper GI tract 
shows a significant correlation of abdomen pain and heart burn to 
oesophagitis and abdomen pain, heart burn,  nausea and vomiting to gastritis. 
The need for an endoscopy of the upper GI tract can never be over 
emphasized keeping in mind the need for proper therapy. It also serves to 
alleviate the fear of a serious disorder and calm the patient. However  
endoscopy requires costly equipment, technical capability and a willing 
patient. Some  patients could not be included as they were not willing for 
endoscopy. In this situation the attending physician is forced to treat 
symptomatically.  
On the basis of this study the combination of upper abdomen pain and 
heartburn was seen in a large percentage of patients having reflux 
oesophagitis and gastritis. Therefore these patients can for practical purposes 
be treated for reflux disease even without a scopy (provided we are sure we 
will not be missing a malignancy). This  would not only be applied to reluctant 
patients but would reduce hospital costs and the medical personnel would 
have more time available. The period of medical treatment can be given for 
twenty one days and patients reviewed in the out patient department. 
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History  is of paramount importance in the diagnosis and treatment of 
upper GI disease. It will help us to exclude certain conditions and zero-in an 
the diagnosis, on a clinical basis. However endoscopy remains the most 
valuable tool for further evaluation. 
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APPENDIX 
PROFORMA 
Name :       Occupation : 
Age & Sex:      Education : 
I.P.No. 
UGI Endoscopy No 
Date of Endoscopy 
HISTORY OF     : 1 / 2 (Preceding 1 Yr) 
Tobacoo (Smoking, Chewing, etc.)   
Alcohol      : 1 / 2 (Preceding 1 week) 
NSAID Use     : 1 / 2 (Preceding 1 week) 
Others 
DIABETIC     : 1 / 2 
HYPERTENSIVE    : 1 / 2 
SYMPTOMS AT PRESENTATION 
a) Upper Abdomen pain / Discomfort : 1 / 2 
b) Heart Burn    : 1 / 2 
c) Early Salary    : 1 / 2 
d) Bloting     : 1 / 2 
e) Vomiting    : 1 / 2 
f) Nausea     : 1 / 2 
g) Anorexia    : 1 / 2 
h) Loss of appetite    : 1 / 2 
i) Dysphagia    : 1 / 2 
j) Belching    : 1 / 2 
k) GI bleeding → Haemetemesis 
   → Malena 
 1 ⇒ Yes 
 2 ⇒  No 
DURATION OF SYMPTOMS :  d / w / m / y (days/weeks/months/years) 
ENDOSCOPIC FINDINGS : 1 / 2 / 3 / 4 / 5 / 6 / 7 / 8 / 9 
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1 Seetha 54 F 2 2 2 2 1 1 1 2 2 2 1 1 2 2 2 2 2 3 m 2 2 2 1 2 2 2 2 2
2 Johnson 35 M 1 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 20 d 1 2 2 2 2 2 2 2 2
3 Vasanthi 32 F 2 2 2 2 2 1 2 2 2 2 1 2 2 2 2 2 2 4 w 1 2 2 2 2 2 2 2 2
4 Vanjammal 45 F 2 2 2 2 2 1 1 1 2 1 1 1 2 2 2 2 2 2 m 2 1 2 1 2 2 2 2 2
5 Narasimma 47 M 1 1 2 2 2 2 1 2 2 2 1 2 2 2 2 2 2 6 m 1 2 2 2 2 2 2 2 2
6 Thenmozhi 18 F 2 2 2 2 2 1 1 2 2 1 1 2 2 2 2 2 2 6 w 1 2 2 2 2 2 2 2 2
7 Thenappan 62 M 1 2 2 1 1 2 1 2 2 2 1 1 2 2 2 2 1 8 m 2 1 2 2 2 2 2 2 2
8 Samsudeen 61 M 1 2 2 2 1 2 2 2 1 1 1 2 1 2 2 2 2 2 m 2 1 2 2 2 2 2 2 2
9 Balachandar 25 M 1 1 2 2 2 1 1 2 1 2 2 1 1 1 2 2 2 1 m 2 1 2 1 2 2 2 2 2
10 Kaladevi 28 F 2 2 2 2 2 1 1 2 2 2 1 2 2 2 2 2 2 3 w 1 2 2 2 2 2 2 2 2
11 vanaja 36 F 2 2 2 2 2 1 1 2 1 2 2 1 1 2 2 2 2 1 M 1 2 2 2 2 2 2 2 2
12 DEVARAJ 52 M 1 1 2 1 1 1 1 2 2 1 1 2 2 2 2 1 1 3 d 2 2 2 1 1 2 2 1 2
13 PREM 18 M 2 2 1 2 2 1 2 2 2 2 2 2 2 2 2 1 2 2 D 2 2 2 2 2 2 1 2 2
14 MANI 55 M 1 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 1 W 1 2 2 2 2 2 2 2 2
15 KISHORE 20 M 1 2 2 2 2 1 2 2 2 2 2 2 1 2 2 2 2 3 W 2 2 2 2 2 2 1 2 2
16 NAVRATNRAJ 63 M 1 2 1 1 1 2 2 2 2 1 1 2 2 2 2 1 2 2 D 2 2 2 2 2 2 1 2 2
17 MUNUSAMY 31 M 1 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 4 M 1 2 2 2 2 2 2 2 2
18 DEVAPUTRI 66 F 2 2 2 1 2 1 2 2 1 1 1 1 2 2 2 2 2 5 w 2 2 2 2 2 2 2 1 2
19 PRAKASH 24 M 1 2 2 2 2 1 1 2 2 1 1 2 1 2 2 2 2 18 m 2 1 2 2 2 2 2 1 2
20 VADIVELU 35 M 2 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 4 m 1 2 2 2 2 2 2 2 2
21 SIVAPRASAD 30 M 2 2 1 2 2 1 1 2 2 2 2 2 2 2 2 2 2 6 w 2 1 2 2 2 2 2 2 2
22 PURUSHOTAM 62 M 1 2 1 1 2 2 2 2 2 1 2 2 2 2 2 1 2 2 d 2 2 2 2 2 2 1 2 2
23 MEHBOOB BEE 68 F 2 2 2 1 1 1 2 2 2 2 1 2 1 2 2 2 2 2 w 2 1 2 1 2 2 1 2 2
24 VENKATIAH 65 M 1 2 2 1 1 1 1 1 1 1 1 1 1 2 2 2 2 1 y 2 2 2 1 2 2 1 2 1
25 SABIRA BEE 42 F 2 2 2 2 2 1 2 1 1 2 2 2 2 2 2 2 2 4 w 1 2 2 2 2 2 2 2 2
26 SRINIVASULU 52 M 2 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 1 w 2 2 2 1 2 2 2 2 2
27 BINU 18 F 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 1 2 3 d 2 2 2 2 2 2 1 1 2
28 THANIKAVEL 28 M 1 2 2 2 2 2 2 2 2 2 2 2 1 2 1 2 2 3 m 1 2 2 2 2 2 2 2 2
29 MUNIAMMAL 68 F 2 2 1 1 1 1 1 1 2 2 2 1 1 2 2 2 2 2 m 2 1 2 2 2 2 2 2 2
30 VENKATESAN 30 M 2 2 2 2 2 1 1 2 2 2 1 2 2 2 2 2 2 3 w 2 2 2 1 2 2 2 2 2
31 BUVANESWARI 40 F 2 2 2 2 2 2 2 2 2 2 2 2 1 1 1 2 2 1 m 2 2 1 2 2 2 2 2 2
32 AROGYA MARY 50 F 2 2 2 2 2 1 2 1 2 2 1 2 2 2 2 2 1 6 m 1 2 2 2 2 2 2 2 2
33 PRAKASH 24 M 2 2 2 2 2 1 1 1 2 1 1 2 1 2 2 2 2 18 M 2 1 2 2 2 2 2 1 2
34 RAJARATNAM 72 M 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 Y 2 2 2 1 2 2 2 2 2
35 NANCY 21 F 2 2 2 2 2 2 2 2 2 1 1 2 2 2 2 2 2 1 M 1 2 2 2 2 2 2 2 2
36 SREEJA 25 F 2 2 1 2 2 1 1 2 2 2 2 2 2 2 2 2 2 3 W 1 2 2 2 2 2 2 2 2
37 THANGAMMAL 80 F 2 2 2 2 2 2 2 2 2 2 2 2 1 2 1 2 2 1 M 1 2 2 2 2 2 2 2 2
38 VEERIAH 78 M 1 2 1 1 1 1 1 2 2 2 1 2 2 2 2 2 2 4 M 1 2 2 2 2 2 2 2 2
39 REKHA 60 F 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 1 1 Y 2 2 2 2 2 2 1 2 2
40 MALLIKARJUN 30 M 1 1 2 2 2 1 1 2 2 1 2 2 1 2 2 2 2 25 D 2 2 2 1 2 2 2 1 2
41 GEORGE 75 M 1 2 2 1 2 1 2 1 1 1 1 1 1 2 1 2 2 7 M 2 2 2 2 2 2 2 2 1
42 BUVANESWARI 30 F 2 2 2 2 2 2 1 2 2 1 1 2 1 2 2 2 2 2 Y 2 1 2 2 2 2 2 2 2
43 SAI KALA 40 F 2 2 2 2 2 1 2 2 2 1 1 2 2 2 2 2 2 2 W 1 2 2 2 2 2 2 2 2
44 VALLI 56 F 2 2 1 1 2 1 2 2 2 2 2 2 2 2 2 2 2 4 W 2 1 2 2 2 2 2 2 2
45 SENTHAMARAI 59 F 2 2 2 2 2 1 1 2 2 1 1 2 2 2 2 2 2 4 W 1 2 2 2 2 2 2 2 2
46 MARAGATHAM 50 F 2 2 2 2 2 1 2 2 2 1 2 2 1 2 2 2 2 6 W 2 2 2 1 2 2 2 2 2
47 GEETHA 48 F 2 2 2 2 1 1 1 2 2 2 1 2 1 2 2 2 2 3 M 1 2 2 2 2 2 2 2 2
48 ARUMUGAM 76 M 1 2 2 2 1 2 2 2 2 2 1 2 2 2 2 2 2 3 W 2 1 2 2 2 2 2 2 2
49 MALATHY 30 F 2 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 5 M 2 1 2 2 2 2 2 2 2
50 RAMESH 26 M 1 2 2 2 2 2 1 1 2 2 1 2 2 2 2 2 2 6 W 1 2 2 2 2 2 2 2 2
51 JOSEPH 41 M 1 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 1 M 2 1 2 2 2 2 2 2 2
52 SHANTAMMA 59 F 2 2 2 2 2 2 1 1 2 2 1 1 2 2 2 2 2 6 M 1 2 2 2 2 2 2 2 2
53 LAXMI 48 F 2 2 2 2 2 2 2 1 1 2 1 1 2 2 2 2 2 4 M 1 2 2 2 2 2 2 2 2
54 DANIEL 81 M 2 2 2 1 2 2 2 2 2 2 2 2 2 1 2 2 2 8 M 1 2 2 2 2 2 2 2 2
55 ESHOK 24 M 2 2 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 3 M 2 2 2 2 2 2 1 2 2
56 AMBALAMMAL 65 F 2 2 1 1 1 1 1 1 1 2 1 1 2 2 2 2 2 6 W 2 2 2 1 1 2 2 2 2
57 RATHI 51 F 2 2 2 2 2 2 2 2 1 2 2 1 1 2 2 2 2 25 D 1 2 2 2 2 2 2 2 2
58 JOTHY 25 F 2 2 2 2 2 1 2 2 2 2 2 2 1 2 2 2 2 3 W 2 2 2 2 2 2 2 1 2
59 GANESAN 32 M 1 1 2 2 2 1 1 2 2 2 1 2 1 2 2 2 2 1 W 2 2 2 2 2 2 2 1 2
60 JEYALAXMI 55 F 2 2 2 2 2 2 1 2 2 1 1 2 1 2 2 2 2 5 M 2 1 2 2 2 2 2 2 2
61 PRABHAVATHY 21 F 2 2 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2 6 W 1 2 2 2 2 2 2 2 2
62 CHOKAMMAL 80 F 2 2 2 1 2 2 2 1 2 2 1 2 2 2 2 2 2 6 M 1 2 2 2 2 2 2 2 2
63 ISMAIL 24 M 1 2 1 2 1 1 1 2 2 2 2 2 2 2 2 2 2 4 W 2 2 2 1 2 2 2 2 2
64 SATISH 29 M 2 2 2 2 2 1 2 2 2 1 1 2 2 2 2 2 2 3 W 1 2 2 2 2 2 2 2 2
65 ANAND RAO 57 M 1 1 2 1 2 2 1 1 2 2 2 1 1 2 2 2 2 1 Y 2 2 2 1 2 2 2 2 2
66 ANANDHI 37 F 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 W 1 2 2 2 2 2 2 2 2
67 RAJESWARI 33 F 2 2 2 2 2 1 2 2 2 2 2 2 1 2 2 2 2 2 M 2 1 2 2 2 2 2 2 2
68 KANNIAMMAL 82 F 2 2 2 1 2 2 1 2 2 2 2 1 1 2 2 2 2 7 M 1 2 2 2 2 2 2 2 2
69 NAGAMMAL 70 F 2 2 1 1 2 1 2 2 2 2 2 1 1 2 2 2 1 1 Y 2 2 2 1 2 2 2 2 2
70 PANNERSELVAM 50 M 1 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 6 W 1 2 2 2 2 2 2 2 2
71 PAARVATHY 60 F 2 2 1 2 1 2 1 2 2 2 2 2 1 2 2 2 1 20 D 2 2 2 1 2 2 2 2 2
72 MUNUSAMY 45 M 1 2 2 2 2 1 1 2 2 2 1 1 2 2 2 2 2 6 W 2 2 2 2 2 2 1 2 2
73 GEORGE 65 M 1 1 2 2 2 2 2 2 2 1 2 2 1 2 2 2 2 3 W 2 2 2 1 2 2 2 2 2
74 ANANDHAN 55 M 1 1 2 2 1 2 2 1 2 2 1 1 2 2 2 2 2 4 M 1 2 2 2 2 2 2 2 2
75 PREMA 44 F 2 2 2 2 2 1 2 2 1 2 2 2 2 2 2 2 2 2 M 1 2 2 2 2 2 2 2 2
76 GEETHA 41 F 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 25 D 1 2 2 2 2 2 2 2 2
77 GEJALAXMI 23 F 2 2 2 2 2 1 2 2 2 1 2 2 2 2 2 2 2 1 Y 1 2 2 2 2 2 2 2 2
78 SIMON FRANCIS 45 M 1 2 2 2 2 1 1 1 2 2 2 2 2 2 2 2 2 7 W 2 2 2 2 2 2 2 1 2
79 VINYAGAM 60 M 1 1 2 1 2 1 1 2 1 2 2 2 1 2 2 2 2 3 W 2 1 2 2 2 2 2 2 2
80 SHANKAR PETER 49 M 2 2 2 2 2 1 1 2 2 2 1 2 2 2 2 2 2 25 D 2 2 2 1 2 2 2 2 2
81 CHITRA 25 F 2 2 2 2 2 2 1 1 1 2 2 2 2 2 2 2 2 2 M 1 2 2 2 2 2 2 2 2
82 RAJALAXMI 23 F 2 2 2 2 2 1 1 2 1 2 1 2 2 2 2 2 2 1 M 1 2 2 2 2 2 2 2 2
83 RAMEEJA 27 F 2 2 2 2 2 1 1 2 2 1 2 2 2 1 2 2 2 2 Y 1 2 2 2 2 2 2 2 2
84 KANAGARATNAM 41 F 2 2 2 2 2 1 2 1 2 2 1 2 2 2 2 2 2 5 W 2 2 2 1 2 2 2 2 2
85 KANNAN 29 M 1 2 2 2 2 1 1 2 1 2 2 1 2 2 2 2 2 4 W 2 2 2 1 2 2 2 1 2
86 JASMINE VIJI 35 F 2 2 2 2 2 1 2 2 2 1 1 2 1 2 2 2 2 25 D 1 2 2 2 2 2 2 2 2
87 SHAHIDA 37 F 2 2 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 W 2 2 2 1 2 2 2 2 2
88 MANOHAR 26 M 2 2 2 2 2 1 2 2 2 2 2 2 2 1 2 2 2 4 Y 1 2 2 2 2 2 2 2 2
89 KALAVATHY 23 F 2 2 2 2 2 1 1 2 2 1 1 2 2 2 2 2 2 6 W 2 1 2 2 2 2 2 2 2
90 VELAYUDHRAJ 22 M 1 1 2 2 2 2 1 2 2 1 1 2 2 2 2 2 2 3 M 2 2 2 1 2 2 2 2 2
91 DHANALAXMI 16 F 2 2 2 2 2 1 2 2 2 2 1 2 1 2 2 2 2 1 Y 1 2 2 2 2 2 2 2 2
92 MANIKAM  80 M 2 2 2 2 2 2 1 2 1 2 2 1 1 2 2 2 2 1 M 1 2 2 2 2 2 2 2 2
93 DEENADAYAL 34 M 1 2 1 2 2 1 1 2 2 1 2 2 2 2 2 2 2 25 D 1 2 2 2 2 2 2 2 2
94 MUNEESWARI 36 F 2 2 2 2 2 1 2 2 2 2 2 1 2 2 2 2 2 7 M 2 1 2 1 2 2 2 2 2
95 GUNASEKAR 54 M 1 1 2 2 2 1 1 2 1 2 1 2 2 2 2 2 2 1 Y 2 2 2 1 2 2 2 2 2
96 SULOCHANA 34 F 2 2 2 2 2 1 2 2 2 1 2 2 1 1 2 2 2 3 M 2 1 2 1 2 2 2 2 2
97 MALADRI 42 M 1 2 2 2 2 1 2 1 1 2 2 2 1 2 2 2 2 1 M 1 2 2 2 2 2 2 2 2
98 ARUMUGAM 76 M 1 2 2 1 2 1 2 2 1 1 1 2 2 2 2 2 2 3 M 2 2 2 1 2 2 2 1 2
99 ALICE 59 F 2 2 2 2 2 1 2 2 2 2 1 2 1 2 2 2 2 6 M 1 2 2 2 2 2 2 2 2
100 DESINGH 54 M 2 2 1 2 1 1 2 2 2 2 2 2 2 2 2 2 2 1 M 2 2 2 2 2 2 2 1 2
101 VASUDEVAN 45 M 1 1 1 2 2 1 1 2 2 2 1 2 2 2 2 2 2 2 W 2 1 2 1 2 2 2 2 2
102 BASKAR 38 M 1 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 1 M 2 1 2 1 2 2 2 2 2
103 ARUMUGAM 31 M 1 2 2 2 2 1 2 2 2 1 1 2 2 2 2 2 2 2 M 2 2 2 1 2 2 2 2 2
104 VIJAYANATHAN 30 M 2 2 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 6 W 1 2 2 2 2 2 2 2 2
105 MANOHAR 38 M 1 2 2 2 2 2 1 2 2 2 1 2 2 2 2 2 2 3 M 2 2 2 1 2 2 1 2 2
106 NAGAMMAL 76 F 2 2 2 1 1 2 1 1 1 2 2 1 2 2 2 2 1 1 Y 1 2 2 2 2 2 2 2 2
107 LATHA 47 F 2 2 1 2 2 1 1 2 2 1 2 2 2 2 2 2 2 5 M 1 2 2 2 2 2 2 2 2
108 LOGANATHAN 72 M 2 2 2 2 2 2 1 2 2 1 1 2 2 2 2 2 2 3 M 2 2 2 1 2 2 2 2 2
109 KARTHIKEYAN 16 M 2 2 2 2 2 1 1 2 2 2 1 2 2 2 2 2 2 2 W 2 2 2 1 2 2 2 1 2
110 SEKAR 46 M 1 2 2 2 2 1 1 2 2 2 2 2 1 2 2 2 2 3 W 2 1 2 2 2 2 2 2 2
111 VIOLET RANI 53 F 2 2 1 1 1 1 2 2 1 2 1 2 1 2 2 2 2 25 D 1 2 2 2 2 2 2 2 2
112 RAJ KUMAR 35 M 1 1 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 W 2 2 2 1 2 2 2 2 2
113 SATYA MORTHY 34 M 2 2 1 2 2 1 2 2 1 2 2 2 2 2 2 2 2 1 W 1 2 2 2 2 2 2 2 2
114 TERRENCE 23 M 2 2 2 2 2 1 1 2 2 1 2 2 2 2 2 2 2 1 M 2 2 2 1 2 2 2 2 2
115 MEENAKSHI 67 F 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 1 3 W 1 2 2 2 2 2 2 2 2
116 SAROJINI 65 F 2 2 1 2 2 1 2 2 2 1 1 2 2 2 2 2 2 4 W 1 2 2 2 2 2 2 2 2
117 INDIRA 57 F 2 2 2 2 2 1 2 2 2 1 2 2 1 2 2 2 2 3 Y 1 2 2 2 2 2 2 2 2
118 SHYAMALA 47 F 2 2 1 2 2 1 2 2 2 1 2 2 1 1 2 2 2 1 M 2 2 2 1 2 2 2 2 2
119 CHANDRAN 28 M 1 2 2 2 2 1 1 2 2 1 2 2 2 2 2 2 2 4 Y 2 2 2 2 2 2 2 1 2
120 ABINANDHAN 30 M 2 2 2 2 2 1 1 2 2 1 1 2 2 2 2 2 2 1 W 2 2 2 2 2 2 2 1 2
121 ROSARY DASAN 44 M 1 2 1 1 2 1 2 2 2 2 1 2 2 2 2 2 2 2 M 2 2 2 1 2 2 2 2 2
122 KUMARASAMY 52 M 2 2 2 2 2 1 1 2 1 2 2 2 1 2 2 2 2 6 M 1 2 2 2 2 2 2 2 2
123 LAXMI 26 F 2 2 2 2 2 1 2 2 2 1 1 2 2 2 2 2 2 2 Y 1 2 2 2 2 2 2 2 2
124 SUDHA 22 F 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 4 W 1 2 2 2 2 2 2 2 2
125 JAMES 76 M 2 2 1 2 2 2 1 2 2 2 2 2 2 2 2 1 2 6 W 1 2 2 2 2 2 2 2 2
126 KADAR BAHADUR31 M 1 1 2 2 2 1 1 2 1 1 1 2 2 2 2 2 2 2 M 1 2 2 2 2 2 2 2 2
127 LOGANATHAN 72 M 2 2 2 2 2 1 2 2 2 1 2 2 1 1 2 2 2 6 M 2 1 2 2 2 2 2 2 2
128 MAN SINGH 25 M 2 2 1 2 2 1 1 2 2 2 1 2 1 2 2 2 2 2 M 2 2 2 1 2 2 2 1 2
129 SHANTI 30 F 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 1 M 1 2 2 2 2 2 2 2 2
130 KONDIAH 39 M 1 2 2 1 2 2 2 2 1 1 1 1 1 2 2 2 2 1 W 2 2 2 1 2 2 2 2 2
131 SIVALINGAM 48 M 1 1 2 1 2 1 1 2 2 2 1 2 2 2 2 2 2 1 Y 2 1 2 2 2 2 2 2 2
132 PRAMILA 50 F 2 2 2 2 2 2 1 1 1 2 2 2 1 2 2 2 2 6 M 1 2 2 2 2 2 2 2 2
133 MANOHAR 45 M 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 D 2 2 2 1 2 2 2 2 2
134 PAPATHIAMMAL 75 F 2 2 2 2 2 1 2 2 2 1 2 2 1 2 2 2 2 2 W 1 2 2 2 2 2 2 2 2
135 SUBRAMANIAM 46 M 2 2 2 2 2 1 1 1 1 2 2 2 2 2 2 2 2 1 W 2 2 2 1 2 2 2 2 2
136 ZULAI KABI 53 F 2 2 2 2 2 1 2 2 2 2 2 2 1 1 2 2 2 6 M 1 2 2 2 2 2 2 2 2
137 KUMAR 30 M 1 2 2 2 2 1 1 1 1 1 1 1 2 2 2 2 2 2 M 2 1 2 2 2 2 2 2 2
138 ELSAMMA 36 F 2 2 2 2 2 1 2 1 1 2 1 2 1 2 1 2 2 4 M 2 2 2 2 2 1 2 2 2
139 JOEL FAITH 22 M 2 2 2 2 2 1 1 2 2 2 2 2 1 2 2 2 2 5 M 2 2 2 1 2 2 1 2 2
140 PRAKASAM 45 M 1 2 1 2 2 1 2 2 2 1 1 2 2 2 2 2 2 4 W 2 2 2 1 2 2 2 1 2
141 MURUGAN 48 M 2 2 1 2 2 1 2 2 2 2 1 2 2 2 2 2 2 1 Y 2 2 2 2 2 2 1 2 2
142 VISWANATHAN 55 M 1 1 2 2 2 1 2 2 2 1 2 2 1 2 2 2 2 5 M 2 1 2 2 2 2 2 2 2
143 RAVI 35 M 1 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 1 M 2 2 2 1 2 2 2 2 2
144 MAHESWARI 30 F 2 2 2 2 2 1 1 2 2 2 1 2 2 2 2 2 2 1 Y 2 1 2 2 2 2 2 2 2
145 DOSS 74 M 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 1 3 M 2 2 2 2 2 2 1 1 2
146 SUNDARARAJ 59 M 2 2 1 2 2 2 1 1 1 2 2 1 2 2 2 2 2 6 W 2 2 2 1 2 2 2 1 2
147 THENMOZHI 35 F 2 2 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 5 M 2 1 2 2 2 2 2 1 2
148 UMA MAHESWAR 38 F 2 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 1 W 1 2 2 2 2 2 2 2 2
149 BALASUBRAMAN 39 M 1 2 2 2 2 2 1 2 2 2 2 2 1 2 2 2 2 2 M 2 2 2 1 2 2 2 1 2
150 SUBADRA DEVI 61 F 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 8 M 1 2 2 2 2 2 2 2 2
151 JOEL  22 M 2 2 2 2 2 1 2 2 2 2 1 2 2 2 2 1 2 2 M 2 2 2 1 2 2 2 2 2
152 SAKKUBAI 60 F 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 3 M 1 2 2 2 2 2 2 2 2
153 KIRUBAVTHY 65 F 2 2 2 2 2 2 2 1 1 2 1 1 1 2 2 2 2 8 W 1 2 2 2 2 2 2 2 2
154 BOOPALAN 48 M 1 1 2 2 2 1 2 2 2 1 1 2 2 2 2 2 2 4 M 2 2 2 2 2 2 2 1 1
155 LINGESWARAN 53 M 1 2 2 2 1 1 1 2 2 2 1 2 2 2 2 2 2 20 D 2 1 2 2 2 2 2 2 2
156 DEENADAYAL 39 M 2 2 2 2 2 1 1 2 2 1 1 2 2 2 1 2 1 6 M 2 2 2 1 2 2 2 2 2
157 ABRAHAM 44 M 1 1 2 2 2 1 2 2 2 1 2 2 2 2 2 2 2 20 D 2 2 2 1 2 2 2 2 2
158 ANNADURAI 45 M 1 2 2 2 2 1 1 2 2 1 2 2 2 2 2 2 2 3 W 1 2 2 2 2 2 2 2 2
159 AMUDHA 35 F 2 2 1 2 2 1 1 2 2 2 1 2 2 2 2 2 2 1 W 2 2 2 1 2 2 2 2 2
160 BALAJI 22 M 2 2 2 2 2 1 2 2 2 1 1 2 1 2 2 2 2 1 Y 2 2 2 1 2 2 2 1 2
161 THANGARAJ 60 M 1 2 1 2 2 1 1 2 2 1 1 2 2 2 2 2 2 4 M 2 1 2 2 2 2 2 2 2
162 YADAV 30 M 1 1 2 2 2 1 1 2 1 1 1 2 1 2 2 2 2 6 M 2 1 2 2 2 2 2 2 2
163 ANSAR BEE 40 F 2 2 2 2 1 1 1 2 2 1 1 2 1 2 2 2 1 2 W 2 2 2 1 2 2 2 2 2
164 MUTHU PANDI 23 M 1 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 M 2 2 2 1 2 2 2 2 2
165 TAMIMA 28 F 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 1 Y 1 2 2 2 2 2 2 2 2
166 SUMATHI 40 F 2 2 2 2 2 1 1 2 2 2 2 1 2 2 2 2 2 2 Y 1 2 2 2 2 2 2 2 2
167 PADMANABAN 55 M 1 1 2 2 2 2 2 2 2 1 1 1 1 2 2 2 2 8 M 2 1 2 2 2 2 2 2 2
168 PORSELVAM 31 M 1 1 2 2 2 1 1 2 2 1 1 2 2 2 2 2 2 2 W 2 1 2 1 2 2 2 2 2
169 BHARATHI 17 F 2 2 2 2 2 1 2 2 2 1 1 2 2 2 2 2 2 3 M 2 2 2 1 2 2 2 2 2
170 KASTHURI 42 F 2 2 2 2 2 1 2 2 2 1 1 2 2 2 1 2 2 2 M 1 2 2 2 2 2 2 2 2
171 RAJAN 32 M 1 1 1 2 2 1 1 2 2 2 1 2 2 2 2 2 2 1 Y 2 1 2 2 2 2 2 1 2
172 SHANTHI 43 F 2 2 2 2 2 2 1 1 1 1 1 2 1 2 2 2 2 2 M 2 1 2 2 2 2 2 2 2
173 NAGAVENI 32 F 2 2 2 2 2 2 1 2 1 2 2 1 2 2 2 2 2 6 W 1 2 2 2 2 2 2 2 2
174 KUMARAN 22 M 1 2 1 2 2 1 2 2 1 1 2 2 2 2 2 2 2 2 M 2 1 2 2 2 2 2 1 2
175 RAJAMANIKKAM 73 M 2 2 2 1 1 1 2 2 2 1 1 2 2 2 2 2 2 6 M 2 2 2 1 2 2 2 2 2
176 CHANDRA 60 F 2 2 2 2 1 2 2 2 2 2 2 2 1 1 1 2 1 2 M 2 2 1 2 2 2 2 2 2
177 SULTANA BEGUM34 F 2 2 2 2 2 1 1 2 1 2 1 2 1 2 2 2 2 1 Y 2 1 2 1 2 2 2 2 2
178 RANI 27 F 2 2 2 2 2 1 2 1 2 2 2 2 2 2 2 2 2 25 D 2 2 2 1 2 2 2 2 2
179 RAVI SANKAR 38 M 1 1 2 2 2 1 2 2 2 1 1 2 2 2 2 2 2 1 W 2 2 2 1 2 2 2 2 2
180 JEYAMMAL 65 F 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 1 2 5 M 2 2 2 1 2 2 2 2 2
181 VISALATCHI 58 F 2 2 2 1 1 1 2 2 1 1 1 2 2 2 2 2 2 1 M 1 2 2 2 2 2 2 2 2
182 PARIMALA 57 F 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 3 M 2 1 2 2 2 2 2 2 2
183 VASUGI 51 F 2 2 1 2 1 1 1 2 1 2 2 2 2 2 2 2 2 2 W 2 2 2 1 2 2 2 2 2
184 VASANTHA 45 F 2 2 1 2 2 1 1 2 2 2 2 2 2 2 2 2 2 1 W 2 1 2 2 2 2 2 2 2
185 ABDUL LATIF 85 M 2 2 2 2 2 2 2 1 1 1 1 2 1 1 1 2 2 1 M 2 2 2 2 2 1 2 2 2
186 MANJULA 27 F 2 2 2 2 2 1 1 1 2 2 1 2 1 2 2 2 2 3 W 1 2 2 2 2 2 2 2 2
187 MOHANA 41 F 2 2 2 2 2 1 2 2 2 2 1 2 1 2 2 2 1 6 M 1 2 2 2 2 2 2 2 2
188 KALPANA 21 F 2 2 2 2 2 1 2 2 2 1 2 2 2 2 2 2 2 2 Y 2 2 2 1 2 2 2 2 2
189 MALLIKA 45 F 2 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 6 M 2 2 2 1 2 2 2 2 2
190 ESTHER 62 F 2 2 2 2 2 1 2 2 2 2 2 2 1 2 2 2 2 3 M 1 2 2 2 2 2 2 2 2
191 AMALORPARANI 31 F 2 2 1 2 2 1 1 2 2 2 1 2 2 2 2 2 2 1 W 2 1 2 2 2 2 2 2 2
192 SUNDARAMBAL 60 F 2 2 1 2 2 2 1 2 2 2 2 2 2 2 2 2 1 20 D 2 2 2 1 2 2 2 2 2
193 PAPPAMMAL 52 F 2 2 2 2 1 2 1 2 2 2 2 1 2 2 2 2 2 2 M 1 2 2 2 2 2 2 2 2
194 JAMES 38 M 1 2 1 2 2 1 1 2 2 2 1 2 1 2 2 2 2 3 M 2 1 2 1 2 2 2 2 2
195 MUNIAMMAL 43 F 2 2 2 2 2 2 2 2 2 1 1 2 2 2 2 2 2 1 M 1 2 2 2 2 2 2 2 2
196 SUSEELA 41 F 2 2 1 2 2 1 1 2 2 2 2 2 2 2 2 2 2 6 W 2 2 2 2 2 2 2 1 2
197 VINOD KUMAR 17 M 2 2 2 2 2 1 1 2 1 2 2 1 2 2 2 2 2 8 M 2 2 2 1 2 2 2 2 2
198 PREMAVATHY 41 F 2 2 2 2 2 1 1 2 2 1 1 2 2 2 2 2 2 3 W 2 1 2 2 2 2 2 2 2
199 CHANDRA 60 F 2 2 2 1 1 2 2 2 2 1 1 2 1 1 2 2 2 2 M 1 2 2 2 2 2 2 2 2
200 UMA  35 F 2 2 2 2 2 1 2 2 1 1 2 1 2 2 2 2 2 3 W 2 1 2 2 2 2 2 2 2
201 BHAVANI 42 F 2 2 1 2 2 1 1 2 2 2 2 2 1 2 2 2 2 2 M 2 1 2 2 2 2 2 2 2
202 SELVI 37 F 2 2 1 2 2 1 2 1 1 1 1 1 2 2 2 2 2 6 M 2 1 2 2 2 2  2 2
203 VIMALA 28 F 2 2 2 2 2 1 2 2 2 1 2 2 2 2 2 2 2 20 D 2 1 2 2 2 2 2 2 2
204 RAJESWARI 17 F 2 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 3 M 2 1 2 2 2 2 2 2 2
205 MADAN KUMAR 23 M 1 2 2 2 2 1 1 2 2 2 2 2 1 2 2 2 2 3 W 2 1 2 1 2 2 2 2 2
206 KOMALAVALLI 31 F 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 25 D 1 2 2 2 2 2 2 2 2
207 AWDESH KUMAR 50 M 1 1 1 2 2 1 1 2 1 2 2 2 2 2 2 2 2 2 W 1 2 2 2 2 2 2 2 2
208 GOPINATH 63 M 1 2 2 2 2 1 2 2 1 2 1 1 2 2 2 2 2 4 M 2 2 2 2 2 2 2 1 2
209 RAMESH 20 M 1 2 2 2 2 1 1 2 2 2 2 2 1 2 2 2 2 3 M 2 2 2 2 2 2 1 2 2
210 SARASWATHY 48 F 2 2 2 2 2 1 2 2 2 1 2 2 2 2 2 2 2 2 W 2 2 2 1 2 2 2 2 2
211 ANKIAH 25 M 1 1 2 2 2 2 2 1 1 1 2 2 2 2 2 2 2 3 M 1 2 2 2 2 2 2 2 2
212 SURESH 32 M 1 2 2 2 2 1 2 2 2 2 1 2 2 2 2 2 2 8 M 2 2 2 2 2 2 1 2 1
213 PADMAVATHY 53 F 2 2 1 2 2 2 2 2 2 1 2 2 2 2 2 1 1 1 W 2 2 2 2 2 2 1 1 2
214 SRINIVASAN 34 M 2 1 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 3 Y 2 2 2 1 2 2 2 2 2
215 VIJAYAKUMARI 52 F 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 5 M 2 1 2 2 2 2 2 2 2
216 SAI  BASKAR 33 M 1 1 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 1 M 2 1 2 2 2 2 2 2 2
217 MARGRET  50 F 2 2 1 2 1 1 1 2 2 1 1 2 2 2 2 2 2 6 W 2 2 2 2 2 2 2 1 2
218 AKBAR PASHA 25 M 1 1 2 2 2 1 1 2 2 2 1 1 1 2 2 2 2 3 W 2 2 2 2 2 2 2 1 2
219 BAALIAH 29 M 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 1 Y 2 1 2 2 2 2 2 2 2
220 KALAVATHY 46 F 2 2 1 2 2 1 1 2 2 2 2 2 2 1 2 2 1 5 Y 2 1 2 2 2 2 2 2 2
221 BAABU 70 M 1 2 2 1 2 2 2 2 2 1 1 2 1 1 2 2 2 25 D 2 1 2 2 2 2 2 2 2
222 DURAI KANNU 69 M 1 2 2 2 2 2 1 1 1 2 2 1 2 2 2 2 2 4 M 2 2 2 1 2 2 2 2 2
223 NEELAMMA 66 F 2 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 1 Y 1 2 2 2 2 2 2 2 2
224 VENKIAH 35 M 1 1 1 2 2 1 1 2 1 2 2 2 1 2 2 2 2 2 M 2 2 2 2 1 2 2 2 2
225 SANTHANAM 55 M 2 2 1 2 2 2 2 2 2 1 2 2 2 2 2 1 2 3 W 2 2 2 1 2 2 2 2 2
226 MANIKANDAN 15 M 2 2 2 2 2 1 2 2 2 1 1 2 2 2 2 2 2 1 W 2 2 2 1 2 2 2 2 2
227 KUMUDHAM 74 F 2 2 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2 4 M 1 2 2 2 2 2 2 2 2
228 ARASUPATHU 35 M 2 2 2 2 2 2 1 2 2 2 1 2 2 2 2 2 2 20 D 1 2 2 2 2 2 2 2 2
229 SAROJAMMA 62 F 2 2 2 1 1 2 2 2 2 2 1 2 1 2 2 2 2 1 M 2 2 2 1 2 2 2 2 2
230 PUSHPA 55 F 2 2 2 1 2 1 2 1 2 1 1 2 1 2 2 2 2 6 M 1 2 2 2 2 2 2 2 2
231 INDHUMATHY 25 F 2 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 6 W 2 1 2 2 2 2 2 2 2
232 RAJESWARI 50 F 2 2 1 2 2 1 2 1 2 2 2 2 1 2 2 2 2 2 M 2 2 2 1 2 2 2 2 2
233 DILLIBAI 42 F 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 3 M 2 2 2 2 2 2 1 2 1
234 ELAVARASI 40 F 2 2 2 2 2 1 2 2 2 1 1 2 2 2 2 2 2 3 M 2 2 2 1 2 2 2 2 2
235 PREMA 44 F 2 2 2 2 2 1 2 2 2 1 2 2 2 2 2 2 2 1 Y 2 1 2 2 2 2 2 2 2
236 SREEDEVI 26 F 2 2 1 2 2 1 2 1 2 1 1 1 2 2 2 2 2 1 M 2 1 2 2 2 2 2 2 2
237 NEETHU 23 F 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 4 W 1 2 2 2 2 2 2 2 2
238 SEBASTIN 38 M 1 1 2 2 2 1 1 2 2 2 1 2 2 2 2 2 2 4 M 2 2 2 2 1 2 2 2 2
239 ASHOK 23 M 1 2 2 2 2 1 1 2 2 2 1 1 2 2 2 2 2 2 W 2 1 2 2 1 2 2 2 2
240 KASTHURI 45 F 2 2 2 2 2 1 1 2 2 2 2 2 2 2 2 1 2 3 D 1 2 2 2 2 2 2 2 2
241 WILSON 36 M 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 6 M 2 2 2 2 2 2 1 2 2
242 BHIMARAJ 40 M 1 1 2 2 2 1 1 2 2 2 2 2 1 2 2 2 2 3 Y 2 1 2 2 2 2 2 2 2
243 UMA RANI 17 F 2 2 1 2 2 1 1 2 2 2 1 2 1 2 2 2 2 1 W 2 2 2 1 2 2 2 2 2
244 LOGAMMAL 66 F 2 2 1 1 1 1 2 2 1 1 2 2 1 2 2 2 2 1 M 2 1 2 2 2 2 2 2 2
245 BASKARAN 42 M 1 2 1 2 2 2 1 2 2 2 1 2 2 2 2 2 2 20 D 2 2 2 1 2 2 2 2 2
246 LOGANAYAGI 60 F 2 2 2 1 2 1 2 2 2 1 1 2 1 2 2 2 2 2 M 2 1 2 2 2 2 2 2 2
247 SHANTHI 36 F 2 2 2 2 2 1 2 2 2 2 2 2 1 2 2 2 2 6 M 2 1 2 2 2 2 2 2 2
248 INDRA MARY 54 F 2 2 1 2 2 2 2 2 2 1 1 2 2 1 1 2 2 5 M 2 2 2 1 2 2 2 2 2
249 MANGALAM 52 F 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 10 M 1 2 2 2 2 2 2 2 2
250 PATTAMMAL 65 F 2 2 2 2 2 2 2 1 2 1 2 2 1 2 1 2 1 3 M 2 2 2 2 2 1 2 2 2
251 SARADHA 65 F 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 3 D 2 2 2 2 2 2 1 2 2
252 JOHN FRANKLIN 31 M 1 1 2 2 2 2 1 2 2 2 2 2 1 2 2 2 2 1 M 1 2 2 2 2 2 2 2 2
253 MUNUSAMY 39 M 1 1 1 2 2 1 2 2 2 1 1 2 2 1 2 2 2 25 D 2 1 2 2 2 2 2 2 2
254 SAKTHI RANI 33 F 2 2 1 2 2 1 1 2 2 1 1 2 1 2 2 2 2 2 W 2 2 2 1 2 2 2 2 2
255 PRAVEEN 18 M 1 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 4 M 2 1 2 2 2 2 2 1 2
256 MUKILAN 25 M 2 2 2 2 2 2 1 2 2 1 1 2 2 2 2 2 2 2 Y 2 1 2 2 2 2 2 2 2
257 MUNIAMMAL 65 F 2 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 1 Y 2 1 2 2 2 2 2 2 2
258 ESWARI 25 F 2 2 1 2 2 1 1 2 2 2 1 2 2 2 2 1 2 2 D 2 2 2 1 2 2 2 2 2
259 SHANMUGAM 25 M 1 1 2 2 2 2 1 1 1 2 2 1 2 2 2 2 2 3 M 2 2 2 1 2 2 2 2 2
260 RAJA PILLAI 39 M 1 2 2 2 2 2 2 1 1 1 1 1 1 2 2 2 2 2 M 2 2 2 2 2 2 2 2 1
261 SHANTAKUMARI 40 F 2 2 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 6 D 1 2 2 2 2 2 2 2 2
262 PETER JOHN 38 M 1 2 2 2 2 2 2 1 2 2 1 2 1 2 2 2 2 4 M 2 1 2 2 2 2 2 2 2
263 JEEVANESAN 61 M 1 2 2 2 2 2 2 2 2 2 2 2 1 2 1 1 1 1 W 2 2 2 2 2 2 1 2 2
264 PALANI 65 M 1 1 1 2 2 2 2 2 2 1 1 2 2 2 2 2 2 1 M 1 2 2 2 2 2 2 2 2
265 PERIASAMY 68 M 1 2 2 1 2 1 1 2 1 1 2 2 1 2 1 2 1 6 M 2 2 2 2 2 2 1 2 1
266 KAMILLA 54 F 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 3 M 1 2 2 2 2 2 2 2 2
267 GHOUSE BEE 50 F 2 2 1 2 2 1 2 1 2 1 1 1 1 2 2 2 2 3 M 2 1 2 1 2 2 2 2 2
268 SUSEELA 65 F 2 2 2 1 1 2 1 2 2 2 1 2 1 2 2 2 2 3 W 2 1 2 2 2 2 2 2 2
269 DURAI  60 M 2 1 2 2 1 2 1 2 2 2 2 2 2 2 2 1 2 4 W 2 2 2 2 1 2 2 1 2
270 PARTHIBAN 40 M 1 1 2 2 2 1 2 2 2 2 1 2 1 2 2 2 2 5 W 2 2 2 1 2 2 2 2 2
271 RATHINAM 78 M 2 1 2 1 1 2 1 2 2 1 2 2 2 2 2 1 1 2 M 2 1 2 1 2 2 2 2 2
272 NARMADHA 26 F 2 2 2 2 2 2 1 2 2 2 1 2 1 2 2 2 2 6 M 1 2 2 2 2 2 2 2 2
273 GANIAN 69 M 1 1 2 2 2 1 2 2 2 1 2 2 2 2 2 2 1 4 W 2 1 2 2 2 2 2 2 2
274 CHANDRAVADAN 64 M 2 2 2 2 2 2 2 2 2 1 2 2 1 1 1 2 2 10 M 2 2 1 2 2 2 2 2 2
275 MUNIAMMA 65 F 2 2 1 2 2 1 2 2 2 2 2 1 2 2 2 2 2 6 M 1 2 2 2 2 2 2 2 2
276 MERCY 40 F 2 2 2 2 2 1 2 2 2 1 2 2 2 2 2 2 2 2 W 1 2 2 2 2 2 2 2 2
277 PRABHU 20 M 1 2 2 2 2 1 1 1 1 2 2 1 1 2 2 2 2 5 M 2 1 2 2 2 2 1 1 2
278 DILLI BABU 35 M 1 2 1 2 2 1 1 2 1 2 2 1 2 2 2 2 2 2 M 2 1 2 2 2 2 2 1 2
279 MUNIAMMA 65 F 2 2 2 2 2 2 1 2 2 2 1 1 1 2 2 2 2 1 M 1 2 2 2 2 2 2 2 2
280 CHRISTY 33 M 1 2 1 2 2 1 1 2 2 2 2 1 2 2 2 2 2 25 D 2 1 2 2 2 2 2 2 2
281 RAMESH 31 M 1 2 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 M 2 2 2 1 2 2 1 2 2
